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ABSTRACT
IDENTIFICATION AND CHARACTERIZATION OF MODULATORS OF HUMAN
MRP1 (ABCC1) AND HUMAN MRP2 (ABCC2) EXPRESSION
VIVIAN OSEI POKU
2021
ATP-binding cassette (ABC) transporters are known to play a critical role in conferring
multidrug resistance (MDR) in various cancers. Several retrospective analyses of
chemotherapy results have reported high expression of Multidrug Resistance Protein 1
(MRP1) and Multidrug Resistance Protein 2 (MRP2) in tumor cells exhibiting the MDR
phenotype. High MRP1 and MRP2 expression in cancer patients predict a higher risk of
treatment failure, resulting in relapse and disease recurrence as well as shortened survival
rates. The key role of MRP1 and MRP2 play in the development of MDR makes them
important therapeutic targets that hold a great promise for addressing multidrug resistance
in cancer cells. Since MRP1 and MRP2 play critical roles in the regulation of various
cellular pathways by altering the levels of several key signaling molecules, finding ways
of modulating the activities and expression of these transporters in cancer cells is of great
clinical interest in oncology research. We identified four novel modulators of MRP1 from
our initial screening of 30 therapeutic compounds using an In-Cell ELISA assay. Three of
these compounds; Amuvatinib, SB743921 HCl, TG101348 (SAR302503), which were
identified to be ATP competitive inhibitors based on their mode of action, decreased MRP1
expression whereas Felbamate (a recently approved FDA drug) increased MRP1 protein
expression. Our findings revealed that these ATP competitive inhibitors decreased MRP1mediated calcein accumulation. These compounds inhibited the growth of HEK293 MRP1-

xix
overexpressing cells at clinically achievable concentrations, and also reversed MRP1mediated resistance in these cells. Since regulation of the activity of activators and effectors
of specific biochemical pathways provide a means of regulating downstream signaling, we
investigated the effect of a novel Tie2 kinase inhibitor and mTOR inhibitor, Everolimus,
on MRP1 activity and expression. Tie2 is an activator of the PI3K/Akt pathway (a pathway
known to modulate MRP1 activity and expression) whereas mTOR is a downstream
effector of this pathway. We demonstrated using a flow cytometry-based calcein
accumulation assay, and MTT based reversal resistance studies that Tie2 kinase inhibitor
and Everolimus can decrease MRP1 mediated calcein efflux and reverse MRP1 mediated
resistance towards vincristine in HEK293 MRP1-overexpressing cells. Lastly, we
identified 49 modulators of MRP2 from our initial screening of 372 FDA-approved drugs
from a recently approved FDA drug library representing 13.17% of total compounds
screened. Thirty-nine (39) drugs increased MRP2 expression whereas 10 drugs lowered
expression of MRP2 after drug treatment. Results from this screening reaffirm the
promiscuous nature of the MRP2 transporter, and how important it is to investigate the
interaction between both old and newly developed drugs with MRP2. The modulators
identified from this study would be further characterized in future projects. Overall, our
findings signify the importance of profiling drug interactions with these transporters, and
the data obtained would provide essential information to improve combinatorial drug
therapy and precision medicine as well as reduce drug toxicity of various cancer
chemotherapies.

1

Chapter 1.0
1.0 Scope of the Study
The main objective and significance of this study is to identify and characterize drugs from
various drug libraries as modulators of Multidrug Resistance Protein 1 (MRP1) and
Multidrug Resistance Protein 2 (MRP2) protein expression in cancer cells. This section
reviews important literature on ATP Binding Cassette (ABC) transporters with a focus on
the ABCC subfamily, their structure, function, and mode of transport. It also details the
role of ABC transporters in the development of Multidrug Resistance (MDR), the role of
modulators in chemotherapy, and some current modulators of ABC transporters as well as
some mechanisms through which protein expression of ABC transporters can be
modulated. This chapter also captures relevant literature on common assays employed in
screening for modulators of ABC transporters such as MRP1 and MRP2. In-cell ELISA
assay, which was the main high-throughput screening tool used in this present study is
carefully examined. Finally, this section concludes by detailing the rationale of this present
study and the essence of identifying modulators of ABC transporters protein expression. It
also describes how findings from this project can be utilized in curbing multidrug resistance
and improving the effectiveness of combinatorial chemotherapy.

2
1.1 Introduction to ABC transporters
One of the largest superfamilies of transporters reported to be present in almost every
kingdom of life is the ATP-binding cassette superfamily of transporters (ABC
transporters). They are described as a diverse and ubiquitous superfamily of transporters
encoded by the ABC genes [1]. ABC transporters function basically as primary-active
transporters, as such they require ATP hydrolysis for their transport activity [2]. These
transporters were previously known as the traffic ATPases [2]. ABC transporters are
reported to facilitate the transport of a broad spectrum of molecules ranging from small
molecules to highly charged and highly hydrophobic molecules such as peptides, lipids,
vitamins [3, 4]. Based on the direction of transport relative to the cytoplasm, ABC
transporters can be classified as importers or exporters [5]. This superfamily of transporters
function as both influx and efflux transporters in prokaryotes, but function mainly as efflux
transporters in eukaryotes. As influx transporters, they are responsible for the influx or
transport of nutrients into the cells. Moreover, as efflux transporters, they are responsible
for the efflux of toxins and drugs across biological membranes [6]. In microorganisms,
ABC transporters have been associated with the development of antibiotic and antifungal
resistance [3].
In humans, 49 ABC transporter proteins have been discovered. These transporters have
been categorized into seven subfamilies based on their amino acid sequence and protein
domain (Table 1.0) [7, 8]. ABC transporters have been reported to play key roles in the
transport of drugs and their metabolites, toxins, steroids, heavy metals as well as aid in
maintaining physiological homeostasis [9]. ABC transporters are expressed in the lungs,
kidney, intestines, and at sacred pharmacological regions like the blood-placenta barrier,
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blood-brain barrier, blood-testis barrier, and the blood-cerebrospinal fluid barrier [10].
Mutation in some ABC transporters have been associated with several human genetic
diseases, and immune deficiencies. Examples include Cystic fibrosis (ABCC7/CFTR),
Stargardt disease and age-related macular degeneration (ABCA4/ABCR), Tangier disease
and familial HDL deficiency (ABCA1), Progressive familial intrahepatic cholestasis
(ABCB11/SPGP),

Dubin-Johnson

syndrome

(ABCC2/MRP2),

Pseudoxanthoma

Elasticum (ABCC6/MRP6), Persistent hypoglycemia of infancy (ABCC8/SUR1),
Sideroblastic anemia (ABCB7), Adrenoleukodystrophy (ABCD1), Sitosterolemia
(ABCG5/ABCG8), Immune deficiency (ABCB2 /Tap1, ABCB3/Tap2) [11].
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Table 1.1: List of subfamilies and members of ABC superfamily
Superfamily

Subfamily
ABCA

ABCB

ABC
Superfamily

ABCC

Members
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A12
A13
B1
B4
B5
B6
B7
B8
B9
B10
B11
TAP2
TAP1
C1
C2
C3
C4
C5
C6
C8
CFTR
C9
C10
C11
C12
C13
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Table 1.1 (Continued): List of subfamilies and members of ABC superfamily.
Superfamily

ABC
Superfamily

Subfamily
ABCD

Members
D1
D2
D3
D4

ABCE

E1

ABCF

F1
F2
F3
G1
G4
G2
G5
G8

ABCG

1.2 Structural organization and function of ABC transporters
Structural analysis reveals that most ABC transporters consist of two sets of membranespanning domains (MSD1 and MSD2) also referred to as the transmembrane domains
(TMDs) and two nucleotide-binding domains (NBD1 and NBD2) [12] (Figure 1.1). The
NBDs consist of two conserved Walker motifs (A and B) regions and a dodecapeptide
region or linker that lies between the Walker motifs known as the C region. The Walker A
and Walker B motifs are reported to be pivotal for ATP binding and hydrolysis [13]. The
Walker A motif specifically binds to ß-γ phosphate of ATP to the Glycine loop of γphosphate linker, whereas the Walker B motif interacts with the magnesium ions. Region
C or the LSGGQ motif serves as the ABC signature motif [14]. A typical MSD consists of
six transmembrane α-helices. The MSDs are responsible for substrate recognition and
translocation across biological membranes [9]. In the ABC superfamily, full transporters
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refer to transporter proteins with at least two MSDs and two NBDs, whereas transporter
proteins with one of each domain are referred to as half transporters. Recent studies have
revealed that some ABC transporters like ABCC1/MRP1 and ABCC2/MRP2 possess an
extra NH2 – proximal membrane-spanning domain known as the MSD0 [15]. The MSD0
contains five transmembrane helices and is reported to help with the retention and recycling
of the transporter to the plasma membrane [16] (Figure 1.1).

Figure 1.1 Structure of ABC transporters.
The membrane-spanning domains; MSD0 (green), MSD1(yellow), MSD2 (red), and
nucleotide-binding domains (NBDs). [A] The predicted topology of half ABC transporters
like BRCP/ABCG2. [B] The predicted topology of ABC transporters like ABCB1/P-gp,
and short MRPs (MRP 4,5,6,8). [C] The predicted topology of ABC transporters having an
extra MSD (MSD0) like long MRPs (MRP1, 2, 3, 6, and 7).
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1.3 The ABCC subfamily
A total of thirteen transporters can be found in this subfamily. These transporters are
referred to as full transporters and are grouped into the multidrug resistance protein
subgroup (9 members), and the sulfonylurea receptor subgroup (SURs, 3 members). The
cystic fibrosis transmembrane conductance regulator (CFTR) can also be found in this
subfamily [17]. The summary of members of this subfamily is listed in table 1.2. Members
of the MRP subgroup can further be categorized into long and short MRPs based on their
predicted topology [18]. The long MRPs are described as transporter proteins that have an
additional NH2-proximal MSD0 to their set of membrane-spanning domains (MSD1 and
MSD2), and two nucleotide-binding domains (NBD1 and NBD2) (Figure 1.1). Examples
of MRPs with this predicted topology include ABCC1/MRP1, ABCC2/MRP2,
ABCC3/MRP3, ABCC6/MRP6, and ABCC10/MRP7. The short MRPs on the other hand
consist of two membrane-spanning domains and two nucleotide-binding domains.
Members with this predicted topology include ABCC4/MRP4, ABCC5/MRP5,
ABCC11/MRP8, and ABCC12/MRP9 [19]. ABCC6 is reported to be associated with the
genetic disease, Pseudoxanthoma Elasticum (PXE) [20]. This disease is characterized by
abnormal accumulation of calcium and other minerals in the elastic fibers of connective
tissues. Mutations in CFTR that cause protein misfolding and abnormal processing provide
the molecular basis of genetic disease, Cystic fibrosis [21]. CFTR plays a key role in
chloride transport. Thus mutation in this gene affects the chloride ion channel function
resulting in dysregulation of epithelial fluid transport in the lungs, pancreas and in other
organs leading to Cystic fibrosis. Loss of ABCC2 activity is also reported to be associated
with the Dubin-Johnson syndrome which is characterized by hyperbilirubinemia.
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Moreover, members of the ABCC subfamily like ABCC1 (MRP1) and ABCC2 (MRP2)
have been associated with the development of multidrug resistance in several carcinomas.
Table 1.2: Summary of members of the ABCC subfamily
ABCC
Subgroup

MRPs

Symbol

Alternative
Name

Tissue Localization

References

ABCC1

MRP1

Ubiquitous (lungs, kidney,
placenta, blood-brain
barrier)

[22, 23]

ABCC2

MRP2

Canicular membrane of
hepatocytes.
Apical membrane of
proximal renal tubule
endothelial cells

[24, 25]

ABCC3

MRP3

Liver, colon, intestine,
adrenal gland

[24]

ABCC4

MRP4

Prostate, testis, ovary,
intestine, pancreas, lung

[11, 26]

ABCC5

MRP5

Skeletal muscle, brain,
heart

[27]

ABCC6

MRP6

Liver, kidney

[28]

ABCC10

MRP7

Liver, peripheral blood
cells, intestines

[29]

ABCC11

MRP8

Breast, lung, colon,
prostate, ovary

[30]

ABCC12

MRP9

Testicular germ cells,
sperms

[31]
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Table 1.2 (Continued): Summary of members of the ABCC subfamily

ABCC
Subgroup

SURs

Symbol

Alternative
Name

Tissue Localization

References

ABCC8

SUR1

Neuronal cells, pancreatic
B-cells

[32]

ABCC9

SUR2

SUR 2A - cardiac and
skeletal muscle

[33, 34]

SUR 2B - vascular smooth
muscle
CFTR

ABCC7

Apical membrane of
epithelial cells in exocrine
glands

[35]

ABCC13

MRP10

Liver, fetal spleen, colon,
placenta, brain, ovary,
liver

[36]

Multidrug Resistance Protein 1 (MRP1) is a 1531 amino acid integral-membrane protein
with a molecular weight of 190-kDa, it is encoded by the gene ABCC1 [37]. MRP1 is
expressed at normal levels in the lungs, kidney, placenta, heart [22, 23], with lower
expression levels observed in the colon, brain, small intestine, and peripheral blood
mononuclear cells. High expression levels of the transporter are observed in cells at various
pharmacological sanctuary sites like the blood-brain barrier, blood-testis barrier, and in the
basolateral membrane of polarized cells [38] as well as in cells with high proliferative
status such as the reactive type II pneumocytes in the alveoli of the lungs [39]. MRP1 as
an ATP-dependent efflux transporter plays a major role in transporting broad spectrum
substrates. These substrates include organic anions, metalloids (sodium arsenite, potassium
antimonite), toxicants (aflatoxin B1, methoxychlor) folic acids, bilirubin, vitamins,
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glutathione and glucuronide-conjugates of steroids, leukotrienes, and prostaglandins B12
[18, 40, 41]. Endobiotics transported by MRP1 include doxorubicin, vincristine, paclitaxel,
ritonavir, irinotecan, methotrexate, saquinavir [41]. Due to the ability of MRP1 to transport
drugs from different multiple families irrespective of their molecular target, structure and
mode of action, MRP1 has been reported to regulate the absorption and disposition of
drugs as well as their metabolites across cells [42]. MRP1 is also reported to be a major
player in the regulation of several physiological processes like redox homeostasis, steroid
metabolism, tissue defense and in the etiology of neurodegenerative and cardiovascular
diseases [43].
MRP2 (ABCC2) on the other hand is also known as canalicular multi-specific organic
anion transporter 1 (cMOAT) [44]. It functions as an ATP-dependent unidirectional efflux
pump and is highly expressed in the liver where it governs the elimination of bilirubin
glucuronides and drug conjugates into the bile. MRP2 is also involved in renal elimination
in the kidneys, and distribution of its substrates in the placenta and the gastrointestinal tract
[45]. It is involved in the transport of numerous clinically important compounds across
multiple drug classes such as antibiotics, HIV drugs, antihypertensives, and anticancer
agents as well as conjugates of lipophilic substances with glutathione, glucuronate, and
sulfate [46]. MRP2 plays a critical role in conferring resistance to various
chemotherapeutics as such it has been implicated in multidrug resistance (MDR) of several
cancers like ovarian, colorectal, lung carcinomas. Moreover, the absence of functional
MRP2 protein leads to Dubin-Johnson syndrome (DJS) associated with conjugated
hyperbilirubinemia [47].
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As members of the long MRPs subgroup, MRP1 and MRP2 possess two nucleotidebinding domains (NBDs) and two membrane-spanning domains (MSDs), and an additional
third N- terminal membrane-spanning domain (MSD0) which comprises of 5
transmembrane spanning helices [26, 48] (Figure 1.1[C]). Studies have shown that MSD0
facilitates interactions between the transporter and other protein partners [49]. Structural
analysis has shown that when these transporters are not bound to any substrate or ATP,
they assume an inward-facing conformation, while the NBDs are widely separated and the
translocation pathway remains continuous with the cytoplasm [50]. On the other hand, the
MSDs get closer to form a high- affinity substrate binding pocket to which the substrate
binds. The NBDs move closer to each other and align themselves for dimerization. ATP
binds to the NBDs, leading to dimerization of the NBDs which causes a conformational
change that results in rearrangement of the MSDs to the outward-facing conformation of
the transporter (rotates and opens towards the extracellular space). Sequentially, the
residues forming the substrate-binding site tend to be pulled apart as the extracellular ends
of the helices of the MSDs peel outward leading to a significant reduction in the binding
affinity of the substrate to the transporter. As a result, the substrate is released into the
extracellular space [50]. ATP hydrolysis begins which causes the dissolution of the closed
NBD dimer conformation. The MSDs move into the open conformation as ADP (adenosine
diphosphate) and phosphate is released [2]. A pictorial diagram of the transport mechanism
of ABC transporters like MRP1 based on the ATP-switch model is shown in Figure 1.2.
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Figure 1.2 Mechanism of ATP mediated transport of ABC exporters based on the
ATP switch model.
The substrate (blue rectangle) binds to the high-affinity binding pocket formed by the
MSDs (yellow and red). This leads to a conformational change in the NBDs (green and
pink), ATP (turquoise hexagon) binds and subsequent NBDs dimer closure occurs. A
conformational change in the MSDs transpires upon the NBDs dimer closure, resulting in
the rotation and opening of the TMDs to the extracellular space, and subsequent substrate
translocation (Step II). The closed NBD dimer conformation is annulled as ATP hydrolysis
commences, leading to conformational changes in the MSDs (Step III). The MSDs move
into the open NBDs dimer conformation as ADP (adenosine diphosphate) and phosphate
is released (Step IV).

1.4 Multidrug resistance and Cancer
Cancer is described as the abnormal and uncontrolled growth of cells. The United States
recorded approximately 599,274 deaths due to cancer in 2018 [51]. Moreover, 18.1 million
new cancer cases were recorded globally in the same year [52]. Although several cancer
treatment options exist, one of the most effective treatment modalities for metabolic tumors
is chemotherapy. Chemotherapy is a type of systemic treatment that involves the use of
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drug formulations to target, control, and kill tumor cells [53]. Although oncology drug
development has seen a paradigm shift from the low-budget, government-supported
research effort to a high-stakes, multi-billion dollar industry [53], the challenge and
limitations of chemotherapy experienced by early research still exist. One of the major
challenges posed to the effectiveness and success of the chemotherapeutic regime is
Multidrug Resistance (MDR). Multidrug resistance is described as a phenomenon in which
tumor cells develop resistance to several drugs that may vary in both structure and mode
of action [54]. Research has revealed that there are several mechanisms involved in the
development of MDR. These include; cellular changes in cells that reduce the ability of the
cytotoxic drug to kill cells such as changes in the cell cycle, elevated repair of DNA
damage, decreased apoptosis occurrence, and altered drug metabolism, decreased uptake
of water-soluble drugs including cisplatin and folate antagonists that need the service of
transporters for cell entry, and increased energy-dependent efflux of hydrophobic drugs
that can diffuse through the plasma membrane into the cell [55]. Studies have shown that
the efflux of hydrophobic cytotoxic drugs by energy-dependent transporters like the ABC
transporters is most common among the mentioned mechanisms. ABC transporters are
major players in the absorption, excretion, metabolism, and elimination of drugs and their
metabolites. For instance, ABC transporters like P-gp, MRP1, MRP2, and BCRP among
others play pivotal roles in phase O and phase III of drug metabolism [5]. In phase O, these
transporters are known to regulate the entry and extrusion of drugs before they reach their
pharmacological target [5]. Moreover, ABC transporters are responsible for the complete
elimination of metabolized molecules in phase III [5]. Transporters like P-gp have been
associated with the transport of cationic drugs and their metabolites, whereas MRP2 and
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BCRP are implicated in the transport of conjugate anionic drugs like conjugated
glutathione across the plasma membrane [56]. The pharmacological aim of administering
chemotherapeutic agents is to ensure the delivery of active compounds as much as possible
to the molecular target in cancer cells to institute sufficient cellular damage to cause cell
death. However, reduction in the intracellular drug accumulation has been reported to be
one of the key factors that decrease the amount of active drug component that reaches these
tumor cells [57]. Due to the essential role played by ABC transporters in drug metabolism,
cancer cells in their intelligence overexpress these transporters as a means of protection
against chemotherapeutic drugs and to ensure their survival. This is accomplished as the
overexpressed transporters cause substantial reductions in the intracellular concentration
of the anticancer drugs resulting in reduced bioavailability and decreased pharmacological
toxicity and potency in cancer patients. As such, MDR remains one of the major barriers
to the effectiveness of chemotherapy and is reported to be responsible for a larger
percentage (about 90%) of cancer related deaths. Thus there is the need for more critical
and careful research to be conducted into the role of ABC transporters in MDR.
Although recent advancement in cancer research has explored the role of transporters like
P-gp and BCRP in MDR to a greater extent, the role of transporters like MRP1 and MRP2
are severely understudied. Recently, several retrospective analyses of chemotherapy results
have reported high expression profiles of MRP1 and MRP2 [58, 59]. In addition,
overexpression of MRP1 and MRP2 has been associated with higher incidence of treatment
failure, resulting in cancer relapse and poor survival rates in some cancer patients [60, 61].
MRP1 is reported to confer resistance to anticancer drugs like methotrexate (MTX),
anthracyclines (doxorubicin), etoposide, vincristine, paclitaxel, vinblastine among others
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[41]. MRP2 also confers resistance to anticancer drugs like cisplatin, irinotecan,
methotrexate, teniposide, mitoxantrone [46]. Aside from anticancer drugs, MRP1 and
MRP2 also affect the bioavailability and efficacy of various antivirals, antimalarials, and
antibiotics [19, 62]. The US food and drug administration recommendation in 2017 greatly
encouraged the need to profile drug-transporter interactions for drugs in clinical trials with
MDR transporter proteins like BRCP and P-gp [63]. But this recommendation excluded
MRP1 and MRP2 although several studies have shown the effect of overexpression of
MRP1 and MRP2 in MDR. Nonetheless, there is no specific recommendation for these
transporters (MRP1 and MRP2) in the current FDA or EMA guidelines. Considering the
essential role of MRP1 and MRP2 as well as their contribution to MDR, it is of great
importance to explore the pharmacological essence and impact of these transporters by
investigating their biochemical interactions with both new and promising drug targets.

1.5 Role of modulators in chemotherapy
The key role of ABC transporters in MDR cannot be overemphasized, as such finding ways
of curbing the menace of ABC transporters in chemotherapy is of great importance to
oncology research. Since ABC transporters are also essential for regulating cellular
function and cellular balance, great consideration must be taken in considering the possible
solutions in managing their role in MDR development. One approach that has been
proposed by researchers is to completely shut down the efflux activity of these pumps.
Although the aforementioned approach seems laudable since overexpression of the ABC
transporter greatly hinders the bioavailability of the therapeutic drugs, this approach would
be suicidal to the cells. This is because ABC transporters also play vital roles in tissue
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defense and maintaining the physiological balance of cells. Thus, a complete shutdown of
these transporters would mean a collapse in physiological stability and equilibrium. An
alternate approach that provides a superior advantage is the modulation of the activity of
ABC transporters in cancer patients through biochemical modulation. Biochemical
modulation involves the modification of pathways and molecular targets by therapeutic
agents to enhance the selective cytotoxic effect of anticancer drugs on tumor cells as well
as to decrease their toxic side effects on normal cells [64, 65]. In clinical oncology research,
biochemical modulation can also be described as a phenomenon in which the cytotoxicity
of an active chemotherapeutic agent is modulated by one or several agents that may not
have inherent cytotoxicity against a given normal or tumor cell population [66].
Modulation via this approach can result in the reduction of the cytotoxicity impact of the
anticancer drug on normal tissues, and an elevation in the cytotoxicity effects of the
anticancer agent on tumor cells. Furthermore, biochemical modulation can also be
employed by using exogenously supplied metabolites to ensure selective manipulation of
tumor cell metabolism to ensure the more selective response to the action of anticancer
agents [67]. Several forms of biochemical modulation have been explored in oncology
research and cancer therapy. This includes modulation to overcome drug resistance in drugresistant cells, modulation of the transport of anticancer agents, modulation of intracellular
thiol levels to affect the extent of damage caused by radiation or chemical DNA damaging
agents, increasing the sensitivity and exposure of tumor cells to chemotherapeutic agents
by modulating the cytokine profile of tumor cells and normal cells [66]. With regards to
overcoming MDR in refractory cancer cells, ligands that interact with ABC transporters
can be grouped into substrates, inhibitors, activators, and inducers. Substrates are small
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molecules or drugs that are effluxed by the transporters. Inhibitors are described as
molecules that decrease or impair the activity of the transporter either by binding directly
or indirectly to it. Inducers are molecules that enhance the expression levels of the
transporter either by altering protein or gene expression levels. Activators are described as
molecules that are reported to elevate the activity of the transporter. Activators exert their
effect by binding to the transporter protein and cause a conformational change which
provokes the transport of a substrate [68]. Via biochemical modulation, the activity of a
specific transporter can be modulated without impacting the physiological steadiness of
normal cells. Moreover, the biochemical modulation approach makes it possible to
combine two or more pharmacological agents that may work by different molecular
mechanisms at their respective effective doses without unacceptable side effects. As such,
an anticancer drug that inhibit the activity of a specific transporter can be used together
with a chemotherapeutic agent that is known to be a substrate of the transporter, yet has
superior therapeutic potency against tumor cells. In this instance, the inhibitor can be used
to decrease the efflux activity of the transporters, allowing the more potent anticancer drug
to accumulate at the appropriate intracellular concentration and be bioavailable to elicit its
effect. Thereby enhancing the effectiveness of combinatorial drug therapy. Combinatorial
therapy is described as the use of two or more pharmacologic agents administered
separately or in a fixed- dose as a single formulation.
1.6 Current modulators of MRP1 and MRP2
MRP1 and MRP2 were discovered several years after the initial characterization of P-gp,
yet there is little scientific information on modulators of MRP1 and MRP2 compared to
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the diverse range of modulators for P-gp that have been well explored and characterized.
Some current modulators of MRP1 and MRP2 are shown in table 1.3
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Table 1.3: Summary of the current modulators of MRP1/ABCC1 and MRP2/ABCC2
Protein/
Gene
name

Substrates

Vinca alkaloids
(vinblastine,
vincristine),
anthracyclines
(doxorubicin,
daunorubicin), taxanes
(paclitaxel),
epipodophyllotoxins
(etoposide, teniposide),
camptothecins
(topotecan,
methotrexate,
irinotecan)
MRP1 glucuronosylbilirubin,
(ABCC) estradiol-17-β-Dglucuronide, etoposideglucuronide, SN-38glucuronide,
leukotrienes C4, D4 and
E4, glutathione
disulfide, prostaglandin
A2-SG,
hydroxynonenal-SG,
aflatoxin B1-epoxideSG, cyclophosphamideSG, doxorubicin-SG,
estrone-3-sulfate,
dehydroepiandrosterone3-sulfate,
sulfatolithocholyl
taurine), difloxacin,
grepafloxacin, folic acid,
L-leucovorin,
mitoxantrone,
curcuminoids, sodium
arsenate, sodium
arsenite, potassium
antimonite, fenitrothion,
methoxychlor, aflatoxin
B1, calcein, fluorescein,
Fluo-3, BCECF,
indinavir, adefovir
Table adapted from [75] and [82]

Inhibitors

Inducers

Activators

Reference

Sulfinpyrazone,
biricodar,
probenecid,
MK571, LTC4,
cyclosporin A,
verapamil, PSC
833,
benzbromarone,
indomethacin,
probenecid,
agosterol A and
analogs,
verapamil
derivatives,
flavonoids
derivatives
(genistein and
flavopiridol),
raloxifenebased inhibitors
(LY117018,
LY329146, and
indomethacin),
piperazine and
piperidinebased
compounds as
dual MRP1/Pgp inhibitors
(N, Ndisubstituted
piperazines),
isoxazole-based
compounds
(LY402913),
quinazolineand
quinaxolinederived
molecules

Dexamethasone,
Verapamil
Rifampicin,
and
Sulindac, Tertderivatives
Butylhydroquinone
(TBHQ),
quercetin,
Vinblastine

[69], [70]
[71],[72]
[73], [74]
[75], [76]
[77], [78]
[79], [80]
[81]
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Table 1.3 (Continued): Summary of the current modulators of MRP1/ABCC1 and
MRP2/ABCC2
Protein/Gene
name

Substrates

Bilirubinglucuronides,
GSSH, GSH,
including
cotransport,
estradiol-17-β-dglucuronide,
MPR2
acidic bile salts.
(ABCC2)
Anionic drug
conjugates,
cisplatin,
doxorubicin,
epirubicin,
etoposide,
indinavir,
phenytoin,
ritonavir,
saquinavir,
sulfinpyrazone,
vinblastine
Table adapted from [75] and [82]

Inhibitors
Probenecid,
Cyclosporine,
PSC833, MK571,
delavirdine,
efavirenz,
emtricitabine,
benzbromarone,
probenecid,

Inducers

Activators

Reference
[82],
[83]

Several decades of research have focused on overcoming MDR via pharmacological
inhibition of ABC transporters like MRP1 and MRP2. However, there has been limited
success due to high non-specific toxicity, low multidrug reversal effects, low potency, and
undesirable off-target effects. Hence, contemporary clinical research strategies aim at
identifying new selective modulators of ABC transporters that are more potent, welltolerated, and have limited non-specific toxicity. Moreover, taking a critical look at the
modulators identified for P-gp, MRP1, and MRP2 in literature, it can be ascertained that
the current knowledge base on MRP1 and MRP2 is still narrow. Thus, it is expedient for
more research to be conducted to identify more potent modulators of MRP1 and MRP2 as
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these transporters also play an essential role in MDR development. Interestingly, most
research studies that aimed at identifying such modulators investigated the impact of these
therapeutic agents on MRP1 and MRP2 activity but hardly examined their effect on protein
or gene expression levels of MRP1 and MRP2. Thus it is needful to explore how such
therapeutic agents may affect protein or gene expression levels since this may also reveal
other molecular targets that may be of great therapeutic importance in our fight against
MDR and cancer.

1.7 Mechanisms for protein expression regulation
Proteins represent one of the abundant macromolecules in living systems. This group of
macromolecules has the most diverse range of functions across the various classes of
macromolecules [84]. Proteins synthesis involves the conversion of information on the
DNA (deoxyribonucleic acid) into messenger RNA (ribonucleic acid, mRNA) through a
process called transcription. After which the information on the mRNA is then converted
into a protein sequence via translation (Figure 1.3). The protein sequence then determines
the protein folding, its conformation, biochemical role, stability, and half-life [84]. The
protein expression levels for a specific protein of interest in the eukaryotic cell can be
regulated at the gene expression level through transcriptional control or by regulating the
translation process.
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Figure 1.3 Protein synthesis illustrating transcription and translation steps
[85]

1.8 Transcriptional regulation
Transcriptional control in the eukaryotic cell can be achieved by transcription factors (TFs)
activation, TFs binding with specific DNA recognition sequences, and chromatin
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remodeling [84]. TFs bind to their target site at once to form the transcription complex,
thus they can regulate several genes disseminated in the genome [86]. TFs can be activated
through small molecules that physically bind or allosterically alter the protein structure
[84]. These small molecules act as modulators of protein expression and function by
depending on specific transcription factors to exert their effect on their target [86].TFs can
also be activated through cellular signaling pathways that create post-transcriptional
protein modifications (PTMs). For instance, translation of the transcription factor, hypoxiainducible factor (HIF-1α and HIF-2α), can be elevated by signaling through the
phosphatidylinositol 3 kinase (PI3K)/Protein kinase B (PKB/Akt) or the PI3K-Akt
pathway [87]. The PI3-Akt signaling pathway also regulates a lot of downstream
transcription factors like NF-kappa B (NF-kB) and activator protein 1 (AP-1) that play key
roles in cell proliferation, cell survival among others in carcinogenesis [88]. TFs activation
is greatly pleiotropic and has many cellular effects, as such several downstream target
genes can be inactivated or activated based on the cell type and environmental conditions.
TFs possess the capacity to rapidly and selectively find their target site. Thus they can bind
to the target DNA site to either institute recruitment of the transcription machinery onto
the promoter region of the gene of interest or hinder the recruitment of the transcriptional
machinery [84]. This can either upregulate or suppress gene expression which in turn
affects translation and protein synthesis.
One way in which transcription can be regulated is via rearrangement of the chromatin
structure. Chromatin consists of nucleosomes. Nucleosomes are described as DNA
wrapped around a histone octamer. Modification to chromatin structure during
transcription can be achieved by histone modifications, eviction or repositioning of
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histones by histone chaperones, chromatin remodeling, and histone variant exchange [84].
Thus, Post-transcriptional modifications (PTMs) in the form of covalent modifications can
be made on the histone tails by histone modifiers. The modifications alter the interaction
and contact between histones and the DNA. Major modifications include acetylation and
methylation of lysine residues. ATP-dependent chromatin remodelers can also use the
energy from ATP hydrolysis to facilitate chromatin remodeling, which can be achieved
through nucleosome sliding, nucleosome displacement, or incorporation and exchange of
histone variants [89].

1.9 Translational regulation
Translation describes the process of converting the information on the messenger RNA
(mRNA) into a protein sequence. The integrity of protein synthesis must be greatly upheld
to ensure minimal error during the process to warrant the synthesis of a functional protein.
Ribosomes are the machinery that ensures the integrity of protein synthesis is upheld with
great care. It achieves this by matching the code from the template mRNA strand to the
right amino acid. Due to the critical role the ribosomes play, the ribosome filter hypothesis
by Mauro and Edelman in 2002 proposes that ribosomes function as translation
determination factors [90]. As such, based on the specific ribosomal proteins and rRNA
sequence in the ribosome complex, they filter and select for specific mRNA that should be
translated. Thus, regulating the translation of these genes into proteins. Considering how
the transcription and translation programs regulate protein expression, it can be seen that
small-molecules if well-investigated and employed can offer the opportunity to modulate
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protein expression levels through either of the aforementioned mechanisms. Hence this
project seeks to provide a methodological alternative to the identification and
characterization of modulators of MRP1 and MRP2 protein expression levels by screening
various therapeutic agents from different drug libraries.
1.10 In vitro assays to screen for modulators of ABC transporters
Identification of interactions between new and promising drugs with ABC transporters is
very essential for drug development. Studying drug-transporter interactions would provide
essential information on how these transporters can impact drug disposition, efficacy, and
toxicity. It would also create a pivotal platform to assist in the selection and optimization
of new drug candidates. In vitro studies of ABC transporters and their interaction can be
carried out via membrane-based assays or cell-based assays. Membrane-based assays
involve the use of membranes made from cells expressing ABC transporters to study the
efflux function of these transporters [75]. Membrane-based assays include membrane
vesicular transport assays, ATPase assays, and photoaffinity labeling assays [69]. Cellbased assays, on the other hand, are performed using intact cells, such assays include;
protein determination assays (In-cell ELISA, western blot), flow cytometry assays,
cytotoxicity assays among others.

1.10.1 In-Cell ELISA assay (ICE)
One of the valuable assays for rapidly characterizing a wide range of cell signaling
parameters in the development of targeted therapeutics is the In-Cell ELISA assay (ICE).
ICE is also known as In-cell western assay, Cell-based ELISA, Cytoblot, or FACE (Fast
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Activated cell-based ELISA). It is cell-based immunocytochemistry that allows the
quantification of target proteins or post-translational modifications of target proteins in
cultured cells (adherent and non-adherent cells). This assay is based on the principle that
using target-specific antibodies, proteins can be detected in fixed and permeabilized
cultured cells. Moreover, the ICE assay bypasses the protein harvesting, lysate preparation,
electrophoretic separation, and electrophoretic transfer steps of western blot. Thus, it
provides a simple and rapid platform for immunodetection of target proteins using
antibodies. Since this assay requires no protein separation, the primary antibodies used
must be highly specific for the protein of interest. This technique also demands the
segregation of signals due to the protein of interest from the normalization signal due to a
reference protein (Actin, Tubulin, Glyceraldehyde -3 – phosphate – dehydrogenase
(GAPDH) into two detection channels [91]. To achieve greater precision, normalization
can be done to correct for well-to-well variation in cell numbers. This can be achieved by
normalizing signals from the protein of interest to an internal control protein/ reference
protein or cell using a cell tag staining (example Cell tag 700) or cell labeling with a
reactive dye. In addition to being simple and rapid, ICE has the added advantage of
amalgamating the specificity of western blot and the replicability and high throughput of
ELISA. As such it can be performed in either 96 or 384 well-formatted plates. Studies
have also shown that ICE yields similar results to western blot whilst providing superior
replicability and precision [91, 92]. Due to its flexibility and high throughput nature, it can
be used for various screening purposes. In this project, ICE was adapted as the major highthroughput tool for screening the various drug libraries that were explored.
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1.10.2 Western blot assay
Changes in the protein expression levels of cells after stimulation can be determined using
traditional western blot. It is one of the common assays used in the detection and
quantification of proteins in biomedical research [93]. In this immunodetection technique,
proteins are first separated and then identified using target-specific antibodies [94]. The
procedure involves the preparation of whole cell lysate from harvested cells and the
separation of proteins based on their molecular weight. The separation of proteins in the
whole cell lysate can be achieved by conducting electrophoresis. The proteins are then
transferred unto a membrane (normally a nitrocellulose or polyvinylidene difluoride
(PDVF)) and exposed to labeled target-specific antibodies [94]. The membrane is then
washed to get rid of unbound antibodies. Antibodies that bind to the protein of interest give
rise to a signal band that is specific for the protein of interest. This band can be detected
using a chemiluminescent or fluorescent substrate. The signal can then be developed as a
film or detected using a camera-based detection. Although the film detection technique is
reported to be robust and sensitive, its dynamic range of quantification is poor compared
to the camera-based detection which offers superior sensitivity and excellent quantification
range [95]. In the western blot assay, the amount of protein present in the sample is
representative of the intensity and thickness of the signal band that is visualized. To cater
for differences in the electrophoresis loading, detection of housekeeping protein like;
tubulin, actin, and GAPDH is performed [96]. Normalization of target signals can be done
using reference signals obtained either from housekeeping proteins (HKPs) after
immunochemical staining or using the total protein (TP) intensity on blotting membranes
after total protein staining [93]. Advantages of this assay include the fact that, it is sensitive
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and the same protein transfer blot can be used for a different analysis of multiple proteins
[75]. However, due to the several processing steps in the western blot assay, it is known to
be a low-throughput and labor-intensive technique [91].

1.10.3 Fluorescence accumulation assays using flow cytometry analysis
The impact of a therapeutic agent on the activity of an ABC transporter can be assessed by
measuring the intracellular accumulation of a fluorescent substrate in cells that overexpress
the ABC transporter of interest, in the presence or absence of a test compound. As such,
fluorescence accumulation assays are one of the tools that have gained popularity in
understanding how various test compounds/drugs can impact the functional activity of
ABC transporters. It is based on the analogy that, there would be a low accumulation of
fluorescent substrate in non-treated cells that overexpress ABC transporters like MRP1, Pgp, and MRP2 among others. This is because the fluorescent substrate is effluxed out of
the intracellular space by the transporter resulting in low fluorescence. However, in the
presence of an inhibitor of the transporter, there would be a high accumulation of the
fluorescent substrate. This is because the inhibitor dampens/decreases the efflux activity
of the transporter, thus leading to an increase in the intracellular fluorescence
accumulation. Low intracellular fluorescence accumulation can also be observed in the
presence of inducers or activators. Since activators only induce conformational changes,
they require less incubation time in eliciting their effect, inducers on the other hand would
require de novo synthesis of the transporter thus they need extended incubation time to
elicit their effect [97]. In most studies, detection using fluorescent substrate is preferred
over radioactive and analytical tools like mass spectrometry because it provides superior
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sensitivity, greater convenience, and lower cost [98]. Visualization of a fluorescent
substrate can be achieved using a fluorescence microscope, however, this method does not
give a quantitative measurement of parameters. A spectrophotometer with fluorescence
abilities can also be used but this approach is also limited by its low sensitivity [98]. One
method that is reported to offer greater sensitivity whilst allowing quantitative
measurement of intracellular accumulation of fluorescent substrates is flow cytometry [99101]. Flow cytometry involves the use of fluorescent dyes and fluorescent antibodies that
can bind to specific cellular components such as proteins on cell membranes or cell surface
molecules among others. It is based on the principle that fluorescently labelled cells when
passed through a light source get excited to a higher energy state. On returning to the
ground/rest state, the fluorochromes emit light energy at higher wavelengths. The
fluorescence emitted is collected by the flow cytometer, spectrally filtered and detected
using a photomultiplier tube [102]. Thus, this technique allows quantitative measurement
of single cells/particles or cellular constituents at high-speed rates [82]. Since test
compounds that emit inherent fluorescence at emission wavelengths similar or close to the
fluorescent substrate can interfere with quantification, it is needful to consider the
background fluorescence of the compounds of interest during quantification. Flow
cytometry can be used to measure the fluorescence and optical characteristics relevant for
the studying of mammalian cells, as such it has become an essential tool for studying the
regulation and interaction of cell systems [75]. Recent advancement in flow cytometry
assays has also paved the way for the use of multiple fluorochromes that emit light at
specific and varying wavelengths but share similar excitation wavelengths. This has
created a platform that enables the measurement of different cell properties concurrently
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[102]. Hence, in the study of ABC transporters, flow cytometry has been commonly
employed in understanding and characterization of the interaction between therapeutic
agents and ABC transporters. Commonly used fluorescent substrates include calcein
acetoxymethyl ester (Calcein-AM) and rhodamine 123, with Calcein-AM being the ideal
reference fluorescent substrate for P-gp and MRP1 studies [103].

1.11 The rationale of the study
There is no doubt that the discovery of modulators of ABC transporters has had several
potential therapeutic benefits especially for patients with drug-resistant tumors. Even
though most identified modulators of ABC transporters had significant effects on
regulating its transport activity, one of the key challenges encountered in clinical trials has
been the efficacy and safety of these modulators. Some dreadful side effects and elevated
levels of patient toxicities have been reported due to adverse pharmacokinetic interactions
with administered anticancer drugs. For instance, the coadministration of cyclosporin A
and etoposide to a patient with acute T-lymphocytic leukemia in relapse resulted in
progressive hyperbilirubinemia and mental confusion [104]. Therefore, there is a need for
more potent, low toxic, and well-tolerated drugs. Moreover, a critical review of literature
on modulators of ABC transporters like MRP1 reveals that although most MRP1
modulators could influence transporter activity, little is known about their impact on the
gene and protein expression levels of these transporters. Thus, further research must be
conducted to investigate how current and future therapeutic agents that interact with ABC
transporters may affect their protein and gene expression levels. This would provide
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essential data on drug-transporter interactions, which is important for clinical trials.
Moreover, therapeutic agents that show the ability to decrease protein expression could be
used together with drugs that are known to be efficacious in treating cancer but are
unfortunately substrates of these transporters. Thus in the presence of the drug that
decreases protein expression of the transporter, the more potent drug would have higher
bioavailability to exert its effect on the cancer cells, thereby enhancing combinatorial drug
therapy. Identification of modulators of ABC transporters like MRP1 and MRP2 would
also enable the scientific community and the pharmaceutical industry to gain greater insight
into the causes of treatment failure and relapses experienced by cancer patients, as well as
provide a possible therapeutic approach to enhance effectiveness of chemotherapy. Aside
from cancer treatment, findings from such studies would provide great enlightenment for
the treatment of other diseases in which these transporters are implicated whilst deepening
our understanding of the pharmacological and physiological nature of these transporters.
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Chapter 2.0
Novel ATP competitive inhibitors downregulate Multidrug resistance protein 1
(MRP1) expression in MRP1- overexpressing cells
Abstract
Multidrug resistance protein 1 (MRP1) is an integral membrane protein that serves as an
ATP-dependent drug efflux pump. It plays a pivotal role in the efflux of a wide variety of
endogenous and exogenous substrates such as toxic chemicals, drugs, and their metabolites
out of cells.

Overexpression of MRP1 confers resistance against commonly used

chemotherapeutic agents in tumor cells. In chemotherapy, the emergence of the
combinatorial therapeutic approach led to a major improvement in survival rates of several
cancers, however multidrug resistance (MDR) has been a major challenge to its
effectiveness. Thus it is of great clinical interest to identify compounds which can modulate
MRP1 expression and activity without perturbing physiological homeostasis. Using an InCell ELISA assay we screened 30 drugs which consisted of both clinically tested anticancer
drugs and recently approved FDA drugs to investigate their effect on MRP1 expression.
We identified a total of 7 modulators, of which 4 test compounds increased the protein
expression levels of MRP1 whereas 3 test compounds decreased the protein expression of
MRP1. Four of the modulators identified (Amuvatinib, SB743921 HCl, TG101348
(SAR302503), Felbamate) have never been reported as modulators of MRP1, thus these
compounds were selected for further characterization in this study. Three of the novel
modulators of MRP1 discovered (Amuvatinib, SB743921 HCl, and TG101348
(SAR302503)) decreased MRP1 protein expression and were identified to be ATP
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competitive inhibitors based on their mode of action. Felbamate (recently approved FDA
drug) increased MRP1 protein expression. Further characterization of our novel
modulators using In-Cell ELISA assay showed that SB743921 HCl and Amuvatinib
decreased MRP1 protein expression in a concentration and time-dependent manner.
Calcein AM accumulation assay performed to ascertain the impact of the selected hit
compounds on MRP1 efflux activity revealed that TG101348 (SAR302503), Amuvatinib,
and SB743921 HCl decreased MRP1 efflux activity. Cell viability and reversal of MRP1mediated resistance to vincristine studies carried out using MTT assay also showed that
TG101348(SAR302503) and Amuvatinib were more potent at reversing MRP1-mediated
resistance. The discovery of key and novel modulators of MRP1 is a step in the right
direction to aid revert MDR in cancer patients. Findings from this project would provide
essential information to improve combinatorial drug therapy and precision medicine as
well as reduce drug toxicity of various cancer chemotherapies.

Keywords: ABC transporters; multidrug resistance; MRP1; ABCC1; MRP1 modulators;
In-Cell ELISA; protein expression; anticancer drug; FDA approved drug; drug profiling;
drug-transporter interactions
1) SB743921 HCl (PubChem CID: 49867937); 2) Amuvatinib (PubChem CID:
11282283); 3) TG101348 (SAR302503) (PubChem CID: 16722836); 4) Felbamate
(PubChem CID: 3331)
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1.0 Introduction
Cancer is the second leading cause of mortality and morbidity globally. In 2018,
approximately 18.1 million new cancer cases, and an estimated 9.6 million cancer-related
deaths were recorded worldwide [1]. Although several treatment modalities exist for cancer
therapy, chemotherapy remains the standard treatment method for various types of cancers.
Chemotherapy is described as the use of drug formulations to target, control, and kill tumor
cells in a systemic treatment module [2]. Even though chemotherapy has been successful
and beneficial in cancer therapy, the challenge of multidrug resistance (MDR) limits its
effectiveness. MDR is a phenomenon in which cells develop resistance to several drugs
that may differ in structure, molecular target, and mode of action [3]. Studies into the
development of MDR revealed several mechanisms that are implicated in this
phenomenon. These mechanisms include; cellular changes in cells that minimize the ability
of cytotoxic drugs to kill cells such as elevated repair of DNA damage and evasion of
apoptosis among others. The other mechanisms reported include decreased uptake of
water-soluble drugs (folate antagonists and cisplatin) that utilize transporter proteins for
cell entry and increased energy-dependent efflux of hydrophobic drugs through the plasma
membrane of cells [3]. One superfamily of transporters whose overexpression has been
implicated in MDR is the ATP-Binding Cassette superfamily of transporters (ABC
transporters). ABC transporters represent a diverse and ubiquitous superfamily of
transporters that utilize ATP hydrolysis for their transport activities [4]. This group of
transporters is known to facilitate the transport of a variety of molecules ranging from small
molecules to highly charged and hydrophobic molecules including peptides, vitamins,
toxins, drugs, and their metabolites across biological membranes [5].
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ABC transporters are present in every phylum of life. Based on their direction of transport
relative to the cytoplasm, they can be categorized into importers and exporters [6]. In
prokaryotes, this group of transporters can function as importers or exporters, however,
they function solely as exporters in eukaryotes. A total of 49 ABC transporters have been
identified in the human genome. These transporters have been classified into seven
subfamilies (A-G) based on their protein domain and amino acid sequence [7, 8]. ABC
transporters like P-glycoprotein (P-gp), Multidrug resistance protein 1 (MRP1), and Breast
cancer resistance protein (BCRP) have been reported to play pivotal roles in the absorption,
excretion, metabolism, and elimination of drug and their metabolites [6]. In phase O and
phase III of drug metabolism, these transporters regulate the entry and extrusion of drugs
before reaching their pharmacological target as well as ensure the complete elimination of
metabolized molecules [6]. As major players in drug metabolism, the overexpression of
some ABC transporters have been implicated in reduced intracellular accumulation and
therapeutic potency in anticancer drugs in cancer patients [9]. The prototypical ABC
transporter is characterized by a transport core consisting of four main domains; two sets
of membrane-spanning domains (MSDs) and two sets of cytosolic nucleotide-binding
domains (NBDs) [10]. The MSD comprises six transmembrane α-helices that form the
substrate-binding site/s and facilitate substrate translocation across the plasma membrane
[11]. The NBDs on the other hand consists of the Walker motifs (Walker A and Walker B)
that bind to ATP for ATP hydrolysis [12]. Upon ATP binding and hydrolysis, the NBDs
dimerize to cause conformational changes that result in the rearrangement of the MSDs to
an outward-facing conformational and subsequent efflux of the substrate. MRPs in the
ABCC subfamilies possess an extra NH2-proximal membrane-spanning domain known as
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the MSD0 [13]. The MSD0 is reported to aid the trafficking, retention and recycling of the
transporter to the plasma membrane [14].
MRP1 is a 190-kDa ATP-dependent efflux transporter [15]. It is expressed in the lungs,
kidney, small intestines, and at pharmacological sanctuary sites including the blood-brain
barrier, blood-testis barrier, and the blood placenta barrier [15-18]. MRP1 localizes at the
plasma membrane and governs the absorption and deposition of a broad spectrum of
substrates [19]. Substrates of MRP1 include heavy metals, toxins, drugs, and metabolites
[20, 21]. The pharmacological aim of administering an anticancer drug is to ensure the
maximum delivery of its active component to the desired therapeutic target in tumor cells,
to initiate enough cellular destruction to cause cell death [9]. However, the overexpression
of ABC transporters like MRP1 facilitates the efflux of such administered anticancer drugs
leading to decreased bioavailability and therapeutic potency of these drugs. As such,
overexpression of MRP1 has been implicated in MDR of many carcinomas and has been
reported to be associated with the elevated risk of treatment failure leading to cancer relapse
and low survival rates among cancer patients [22]. In addition to conferring resistance to
anticancer drugs like paclitaxel, etoposide, and doxorubicin, MRP1 also affects the
bioavailability and efficacy of antivirals, antimalarials, antibiotics [23]. Aside the critical
role MRP1 plays in MDR, it also aids in maintaining physiological homeostasis by
regulating redox homeostasis, steroid metabolism among others [24]. MRP1 also acts as a
key player in the etiology of neurodegenerative diseases like Alzheimer's disease and
cardiovascular diseases [24].
Biochemical modulation plays a key role in chemotherapy. It is described as the process in
which pathways or molecular targets are biochemically modified by therapeutic agents to
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enhance the selective cytotoxic effect of anticancer agents on cancer cells but decrease their
toxic side effects on normal cells [25, 26]. Biochemical modulation offers a means of
regulating the activity of ABC transporters like MRP1 without perturbing the physiological
balance in normal cells. Moreover, modulators also have the added advantage of boosting
oral availability and enhancing the penetration of drugs that are transported by MRP1 in
tissues [27]. In this present study, we screened 30 drugs consisting of both anticancer and
recently approved FDA drugs to ascertain their effect on MRP1 protein expression levels
using In-Cell Enzyme-Linked Immunosorbent assay (In-Cell ELISA) assay. We identified
4 novel drugs that modulated MRP1 protein expression in MRP1-overexpressing cells.
These drugs included 3 novel ATP competitive inhibitors that down-regulated MRP1
protein expression and one FDA approved drug that increased MRP1 protein expression.
The ability of test compounds to modulate MRP1 activity and reverse MRP1-mediated
resistance was further explored using established methods.
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2.0 Materials and methods
2.1 Chemicals
Test compounds consisting of anticancer and FDA approved drugs were procured from
Selleck Chemicals (Houston, TX), and APExBIO Technology LLC (Houston, TX).
MK571 was acquired from APExBIO Technology LLC (Houston, TX), thiazolyl blue
tetrazolium bromide (MTT) was procured from Sigma-Aldrich (St. Louis, MO) and
Calcein acetoxymethyl ester (Calcein AM) was obtained from Corning Life Sciences
(Corning, NY).

2.2 Cell lines and cell culture
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD). Dulbecco’s modiﬁed Eagle medium (DMEM) (GE
Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine serum (FBS)
was used to grow the HEK293 cell lines. Cell lines were cultured in a humidiﬁed incubator
maintained at 5% CO2 at 37 °C. This incubation condition was retained in all subsequent
cell culture procedures.

2.3 Screening of compounds using In-Cell ELISA assay
In-Cell ELISA assay was used to screen the test compounds for modulators of MRP1
protein expression. HEK293/pcDNA3.1 and HEK293/MPR1 cells were seeded at a cell
density of 5 x 104 cells per well in 96-well plates with DMEM containing 10% FBS, treated
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with drugs (10 uM), and 0.1% DMSO (controls) after 24 hours, Cells were incubated for
48 hours after drug treatment at 37 °C. At the end of the incubation period, treatments were
removed and cells were rinsed twice with 150 μl of PBS. Cells were fixed with 3.7%
paraformaldehyde and permeabilized with Triton X-100. The cells were blocked using fish
gel (MB-066-0100, Rockland) and incubated overnight at 4 °C with monoclonal antiMRP1 antibody (1:500; IU5C1, MA516079, Thermo Fisher Scientific) or anti-α tubulin
antibody (1:1000; T5168, Sigma -Aldrich) used as the internal control. Horseradish
peroxidase-conjugated goat anti-mouse secondary antibody (Thermo Fisher Scientific) was
incubated for an hour at room temperature. Target proteins were detected with
chemiluminescence using Super signal West Dura® Extended Duration Substrate
(21EAPI34076, Thermo Fisher Scientific) and read using Hidex Sense Beta Plus plate
reader (Turku, Finland). Experiments were conducted in two independent studies, with
treatments performed in duplicates.

2.4 Determination of the concentration-dependent activity of selected hit compounds
on MRP1 protein levels using In-Cell ELISA assay
HEK293 MRP1 overexpressing cells and HEK293/pcDNA3.1 cells were seeded in 96-well
plates as described earlier. Cells were treated with varying concentration of test
compounds;1 µM, 5 µM, 10 µM, 20 µM and incubated at 37 °C for 48 hours. Final DMSO
concentration was maintained at less than 0.2% (v/v). Cells were fixed, permeabilized, and
blocked as detailed earlier. Incubation with monoclonal anti-MRP1 antibody (1:250;
IU5C1, MA516079, Thermo Fisher Scientific) and anti-α tubulin antibody (1:1000, T5168,
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Sigma-Aldrich) was conducted overnight at 4 °C. Horseradish peroxidase-conjugated goat
anti-mouse secondary antibody incubation was performed for an hour at room temperature.
Target proteins were detected using western blotting luminol reagent (Santa Cruz
Biotechnology, sc-2048), and read using Hidex Sense Beta Plus plate reader (Turku,
Finland). Treatments were done in triplicates.

2.5 Time-dependent activity of selected hit compounds on MRP1 Protein levels using
In-Cell ELISA assay.
HEK293/MRP1 and HEK293/pcDNA3.1 cells were seeded as detailed above and treated
with 10µM of test compounds and incubated for various time points; 12, 24, and 48 hours
at 37°C. Controls were treated with 0.1% DMSO. Cells were fixed, permeabilized, and
blocked as indicated earlier. After which, cells were incubated with monoclonal anti-MRP1
antibody (1:250; IU5C1, MA516079, Thermo Fisher Scientific) and anti-α tubulin
antibody (1:1000, T5168, Sigma-Aldrich) was conducted overnight at 4 °C. Followed by
incubation with horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) for an hour
at room temperature. Western blotting luminol reagent (Santa Cruz Biotechnology, sc2048) was used for detection of target proteins, and plates were read using Hidex Sense
Beta Plus plate reader (Turku, Finland). Treatments were performed in triplicates.

2.6 Flow cytometric measurements of intracellular Calcein accumulation
Flow cytometry was conducted to determine the effect of selected drugs on MRP1
mediated efflux of calcein-AM. Calcein-AM was used as the fluorescent substrate for the
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accumulation assay, with MK571 as the positive control. HEK293/MRP1 cells were
prepared in serum-free medium at a cell density of 7×105 cells/ml and treated with test
compounds (10μM final concentration), MK571 (25 μM final concentration), and DMSO
(0.1% final concentration for controls). Cells were incubated at 37 ⁰C for 10 minutes. After
incubation, the cells were treated with Calcein-AM (0.25 µM) and incubated for additional
30 minutes. Ice-cold PBS buffer (3 ml) was added to halt the reaction, after which cells
were centrifuged and washed twice with cold PBS. Cells were then resuspended in a cold
PBS buffer containing 1% paraformaldehyde. Detection of intracellular accumulation of
calcein-AM was done using a BD Accuri C6 flow cytometer ( BD Biosciences, San Jose,
CA) with excitation at 480 nm, and emission and 533/30 nm. Fluorescence intensities are
representative of the mean value collected from 10,000 events. Treatments were done in
duplicates and conducted in three independent experiments.

2.7 Cytotoxicity of selected test compounds
The sensitivity of HEK293/MRP1 and HEK293/ pcDNA3.1 cells towards the selected test
compounds were determined using the MTT colorimetric assay. Cells were seeded at a cell
density of 5 × 103 per 100 ul of culture medium in 96 well plates. After 24 hours, cells were
treated with 100ul of test compounds at varying concentrations. The final DMSO
concentration was kept at 0.05%. Cells were then incubated for 72 hours, after which 100
ul of the spent culture medium was carefully removed. Cells were then treated with MTT
(0.5 mg/ml) for 4 hours. The formazan crystals were dissolved by the addition of 100 ul of
15% SDS containing 10 mM HCl and absorbance at 570 nm was recorded using a Hidex

56
Sense Beta Plus plate reader (Turku, Finland). Treatments were done in triplicates, and
experiments were performed in two independent studies.

2.8 Resistance reversal assay
The ability of test compounds to reverse MRP1 mediated resistance towards the
chemotherapeutic drug, vincristine was analyzed using the MTT colorimetric assay. Cells
were seeded in 96 well plates at a cell density of 5 × 103 per 100 ul of culture medium.
After 24 hours, cells were treated with 50 ul of test compounds at selected concentrations
prepared in a culture medium. After an hour, 50 ul of vincristine at varying concentrations
was added to the cells. Final DMSO was maintained at 0.2%, and cells were incubated for
72 hours. At the end of the incubation period, 100 ul of the spent culture medium was
carefully removed. Cells were treated with MTT (0.5 mg/ml) for 4 hours. The formazan
crystals were dissolved by the addition of 100 ul of 15% SDS containing 10 mM HCl and
absorbance at 570 nm was recorded using a Hidex Sense Beta Plus plate reader (Turku,
Finland). Treatments were done in triplicates, and experiments were performed in two
independent studies.

2.9 Statistical analysis
Statistical analysis was performed using GraphPad Prism TM software (GraphPad
Software version 8.4.3, San Diego, CA, USA). The differences between mean values were
analyzed using linear mixed model analysis. Sidak correction was applied for multiple
comparisons, statistical testing was performed at a 5% level of significance.
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3.0 Results
3.1 Screening for modulators of MRP1 protein expression using In-Cell ELISA assay
In-Cell ELISA also known as In-cell western assay or Cytoblot is a cell-based
immunocytochemistry assay that allows quantification of target proteins in cultured cells.
It merges the specificity of western blot, the replicability, and the high-throughput nature
of ELISA. To identify modulators of MRP1 protein expression levels, we screened 30
drugs (consisting of both clinically tested anticancer and recently approved FDA drugs)
using In-Cell ELISA assay in HEK293 MRP1-overexpressing cells. The MRP1 protein
expression in HEK293/MRP1 treated with 0.1% DMSO was considered as the baseline for
computing the percent modulation for the test compounds. The screening was conducted
in 96-well format in two independent studies. The percent modulation of MRP1 protein
expression by the test compounds from the two independent studies is represented in Figure
2.1. A test compound was considered as a “Hit compound” if its calculated percent
modulation is ≥ 30% in the positive (+) or negative (-) direction. Test compounds that
showed percent modulation ≥ 30% are presented as red dots in Figure 2.1, whereas drugs
that showed percent modulation < 30% are represented by black dots. The screening
process identified a total of 11 hit compounds that modulated the protein expression of
MRP1 ≥ 30%. The identified hit compounds, their therapeutic targets, and specific percent
modulation are listed in table 2.1.
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Figure 2. 1. Screening of compounds using In-Cell ELISA assay.
HEK293/MRP1 cells were treated with 10 µM of test compounds and incubated for 48
hours. MRP1 protein expression was detected using a monoclonal anti-MRP1 antibody
(1:500; IU5C1, MA516079, Thermo Fisher Scientific). Alpha-tubulin protein (used as an
internal control) was detected using mAb α-tubulin (1: 1000; T5168, Sigma – Aldrich).
Secondary antibody; mAb-goat-anti-mouse (1:1000) was used. Treatments were
performed in duplicates and experiments were conducted in two independent studies. Red
dots represent drugs that showed ≥ 30% modulation of MRP1 protein expression. Black
dots represent drugs that showed < 30% modulation of MRP1 protein expression.
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Table 2.1 Modulatory effect of drugs on MRP1 protein expression
Compound

Target

% Modulation on MRP1
protein expression

Saracatinib (AZD0530)

Bcr-Abl

-2.88 ± 0.08

Linifanib (ABT-869)

CSF-1R

-12.23 ± 0.14

Zonisamide

T-type calcium channels

0.47 ± 0.16

Axitinib*

c-Kit

-40.80 ± 0.09

XMD8-92

ERK

5.17 ± 0.09

PI-103

Autophagy

13.88 ± 0.04

Vandetanib (Zactima)

VEGFR

-12.09 ± 0.12

Amuvatinib***

c-Kit

-50.70 ± 0.01

Epirubicin HCl*

Topoisomerase

75.19 ± 0.07

Trichostatin A (TSA)

HDAC

-25.00 ± 0.10

LY294002

Autophagy

-12.67 ± 0.06

Sunitinib Malate (Sutent)

c-Kit

21.04 ± 0.05

SU11274

c-Met

-27.38 ± 0.02

Nutlin-3

E3 Ligase

-18.15 ± 0.07

PCI-24781*

HDAC

-44.22 ± 0.1

Iniparib (BSI-201)

PARP

-7.239 ± 0.11

Vismodegib (GDC-0449)*

Hedgehog

-56.79 ± 0.12

SB 743921 HCl***

Kinesin

-60.30 ± 0.05

Irinotecan*

Topoisomerase

76.98 ± 0.09

Atazanavir sulfate

HIV protease

20.85 ± 0.12

Bumetanide

Na+-K+-Cl- cotransporter

-10.51 ± 0.02

VER-50589

HSP

-20.25 ± 0.09

Felbamate***

NMDA receptor

93.54 ± 0.20

a

Mean ± SEM of n ≥ 2 independent experiments.

* Hit compounds – showed ≥ 30% modulation
***Hit compounds characterized – showed ≥ 50% modulation

a
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Table 2.1 (Continued) Modulatory effect of drugs on MRP1 protein expression
Compound

Target

% Modulation on MRP1
protein levels

Tadalafil (Cialis)

PDE

-0.97 ± 0.02

PF-04217903

c-Met

-4.50 ± 0.06

Telaprevir (VX-950)*

HCV Protease

41.90 ± 0.03

Saxagliptin (BMS-477118Onglyza)

DPP-4

13.84 ± 0.04

Pimobendan (Vetmedin)*

PDE

34.03 ± 0.04

TG101348 (SAR302503)***

JAK

-55.11 ± 0.06

Vatalanib 2HCl (PTK787)

c-Kit

24.68 ± 0.01

a Mean

a

± SEM of n ≥ 2 independent experiments.

* Hit compounds –showed ≥ 30% modulation
***Hit compounds characterized – showed ≥ 50% modulation

Out of the 11 hits identified, 5 test compounds increased the protein expression levels of
MRP1 and 6 test compounds decreased the protein expression of MRP1. For detailed
characterization, hit compounds that modulated protein expression of MRP1 ≥ 50% were
considered. Seven of the hit compounds showed modulation of MRP1 protein expression
≥ 50%. Among these hits, three compounds (Vismodegib, Epirubicin HCl, and Irinotecan)
have already been reported to modulate MRP1 in other studies [28-30]. Thus, these
compounds were not further characterized. In this study, we focused on characterizing the
other 4 novel test compounds that to the best of our knowledge have not been reported for
their activity as modulators of MRP1 protein expression (Table 2.2). This included 3 ATP
competitive inhibitors; SB743921 HCl, Amuvatinib, TG101348 (SAR302503), and an
FDA approved drug, Felbamate. SB743921 HCl, Amuvatinib, and TG101348
(SAR302503) decreased MRP1 protein expression levels by 60.30%, 50.70%, and 55.11%
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respectively, with SB743921 HCl eliciting the highest negative modulation of MRP1
protein levels. Felbamate on the other hand increased MRP1 protein expression levels by
93.54 % in the HEK293 overexpressing MRP1 cells. The chemical structures of the
selected compounds are shown in Figure 2.2.

Table 2.2 Chemotherapeutic targets, % modulation of MRP1 protein expression for
selected and characterized Hit compounds
Compound

Chemotherapeutic
targets

% Modulation MRP1

SB743921 HCl

Kinesin

60.30 ± 0.05

Decrease

Amuvatinib

C-kit

50.70 ± 0.01

Decrease

TG101348
(SAR302503)

JAK

55.11 ± 0.06

Decrease

Felbamate

N-Methyl-D-aspartate
(NMDA) receptor

93.54 ± 0.20

Increase

a

Mean ± SEM of n ≥ 2 independent experiments

protein levels

a

Effect on MRP1
protein levels
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SB743921 HCl

TG101348 (SAR302503)

Amuvatinib

Figure 2.2 Chemical structures of selected hit compounds

Felbamate
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3.2 Concentration and time-dependent activity of selected hit compounds for MRP1
In order to determine if the modulatory effects observed for our selected compounds were
concentration and time-dependent and to identify the conditions that produce the maximum
modulatory effect, we conducted concentration and time-dependent studies using the InCell ELISA assay. HEK293 MRP1 overexpressing cells were treated with varying
concentration (1 µM, 5 µM, 10 µM, 20 µM) of the test compounds for the concentrationdependent studies. In the time-dependent studies, cells were treated with 10 µM of test
compounds, and were incubated at various time points; 12 hours, 24 hours, and 48 hours.
As shown in Figure 2.3A; expression levels of MRP1 were further reduced by increasing
concentrations of SB743921 HCl and Amuvatinib. Drug treatment of 20 µM exhibited
strongest modulatory effect and resulted in 75.62 % and 85.28% reduction in MRP1
expression by SB743921 HCl and Amuvatinib, respectively. TG101348 (SAR302503)
showed highest downregulation of MRP1 protein expression at 10 µM. Treatment with
Felbamate also showed concentration dependence and highest modulatory effect on MRP1
expression levels was observed in case of 10 µM drug treatment. Regarding timedependence studies, as presented in Figure 2.3B, all drug treatments demonstrated timedependence and the highest modulatory effect was observed with 48 hour treatment.
Therefore, in case of SB743921 HCl, Amuvatinib and TG101348, MRP1 expression levels
were reduced by 62.83%, 49.29% and 49.28% respectively by 48 hour drug treatment. In
the case of Felbamate, MRP1 expression levels were increased by 77.90% by 48 hour drug
treatment.
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Figure 2.3 Concentration and time-dependent activity of selected hit compounds on MRP1 protein

expression using In-Cell ELISA assay.
[A] Concentration dependent activity of test compounds on MRP1 protein expression; HEK293/MRP1
cells were treated with 1 µM, 5 µM, 10 µM and 20 µM of test compounds and incubated for 48 hours. [B]
Time dependent activity of selected hit compounds on MRP1 protein expression, HEK293/MRP1 cells
were treated with 10 µM of test compounds and incubated for 12, 24, 48 hours. Treatments were performed
in triplicates and data analyzed using linear mixed model and Sidak post hoc test. Data is represented as

mean ± S.D. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared to control.
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3.3 Effect of test compounds on MRP1 efflux activity using calcein accumulation assay
Overexpression of MRP1 has been associated with the increased efflux of multiple classes
of therapeutic agents across biological membranes. This results in the low bioavailability
and reduced pharmacological potency of such compounds. We investigated the effect of
the selected compounds on MRP1 efflux activity of calcein-AM using a flow cytometrybased assay. Calcein-AM is a well-known substrate of MRP1. This non-fluorescent
compound is converted into a highly fluorescent molecule when its acetoxymethyl ester
(AM) component is cleaved off by cellular esterases. Using flow cytometry, the
intracellular calcein fluorescence accumulation can be ascertained. In this assay,
HEK293/MRP1 cells were treated with 10 µM of the test compounds for 10 minutes before
the treatment with calcein-AM was conducted for an extra 30 minutes. Our results as
presented in Figure 2.4 shows that 25 µM of MK571 (commonly used MRP1 inhibitor)
increased intracellular calcein-AM by 3.85-fold compared to the no treatment control.
Among the selected compounds; SB743921 HCl, Amuvatinib, and TG101348
(SAR302503) significantly increased the calcein accumulation by 3.51-fold, 1.75-fold, and
2.52-fold respectively with SB743921 HCl exhibiting highest modulatory effect on MRP1
activity compared to no treatment control. Felbamate, on the other hand, did not have any
significant impact on calcein accumulation as compared to the no treatment control.
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Figure 2.4 Effect of selected hit compounds on MRP1 mediated calcein efflux.
HEK293/MRP1 cells were treated with 10 µM of the test compounds, and 25 µM of
MK571 (positive control) for 10 minutes at 37°C before treatment with 0.25 µM calceinAM for 30 minutes. Flow cytometric measurements of intracellular calcein-AM was
conducted at 488 nm and 533/30 nm for excitation and emission wavelengths, respectively.
Experiments were done as duplicates in three independent experiments and presented as
mean ± S.E.M. Data was analyzed using a linear mixed model and Sidak post hoc test. *P
< 0.05; **P < 0.01; ***P < 0.001 compared to control.
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3.4 In vitro cytotoxicity of selected test compounds
The half-maximal inhibitory concentration (IC50) is a measure of the effectiveness of a
specific compound to inhibit a specific biochemical or biological function. Results from
the cytotoxicity studies using MTT as shown in table 2.3, reveals that Amuvatinib was the
most potent in inhibiting the growth of HEK293/MRP1 cells with an average IC50 of 2.64
µM. TG101348 (SAR302503) with an average IC50 of 3.26 µM was also very potent in
inhibiting the growth of HEK293/MRP1 cells. SB743921 also showed an inhibitory effect
on HEK293/MRP1 cells with an average IC50 of 9.35 µM. Felbamate had the least growth
inhibitory effect on HEK293/MRP1 cells with an average IC50 of 47.23 µM. Thus from
table 2.3, we can infer that most HEK293/MRP1 cells survived when treated with
felbamate hence requiring very high concentration of the drug to inhibit 50% of the cell
growth. As expected HEK293/pcDNA 3.1 was very sensitive to the cytotoxic activity of
all the test compounds as compared to HEK293/MRP1 cells since they do not overexpress
MRP1, thus these cells can easily be impacted by the cytotoxicity of the drugs. Overall, the
three ATP competitive inhibitors that decreased MRP1 protein expression were also very
potent in inhibiting the cell growth of HEK293 MRP1-overexpressing cells.
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Table 2.3 Cytotoxicity of selected hit compounds on HEK293/pcDNA3.1 and
HEK293/MRP1 cells
Cell Line

HEK293/pcDNA3.1

HEK293/MRP1

a

a

Drug

IC50 (µM)

SB743921 HCl

6.84 ± 0.73

Amuvatinib

0.45 ± 0.25

TG101348 (SAR302503)

2.05 ± 0.34

Felbamate

14.92 ± 2.06

SB743921 HCl

9.35 ± 0.12

Amuvatinib

2.61 ± 0.64

TG101348 (SAR302503)

3.26 ± 0.21

Felbamate

47.23 ±0.64

Mean ± SEM of n ≥ 2 independent experiments

3.5 Effect of selected test compounds on MRP1-mediated drug resistance
One of the major setbacks of the current modulators of MRP1 is the fact that they exhibit
low MDR reversal effects. Thus, we investigated the ability of the selected compounds to
reverse MRP1 mediated resistance towards vincristine. HEK293 MRP1-overexpressing
cells were treated with varying concentrations of vincristine in the presence or absence of
non-cytotoxic concentrations of the test compounds. MK571 was used as positive control.
As shown by the IC50 and fold resistance listed in table 2.4. HEK293 MRP1-overexpressing
cells in the absence of MK571 demonstrated very low sensitivity to the cytotoxicity effect
of vincristine, giving a high fold resistance of 20.51 fold. HEK293/pcDNA3.1
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contrastingly exhibited very high sensitivity towards vincristine, thus gave a very low fold
resistance. In the presence of MK571 inhibitor (25 µM), the fold resistance in the MRP1overexpressing cells drastically decreased from 20.51 to 3.64-fold resistance. From the
results obtained, two of the selected compounds; Amuvatinib and TG101348
(SAR302503) at 1 µM reversed MRP1-mediated resistance towards vincristine in
HEK293/MRP1 cells. TG101348 (SAR302503) strongly decreased the fold resistance to
7.16-fold, whilst Amuvatinib also reduced the fold resistance to 9.13-fold. This indicated
that our selected test compounds may be able to reverse MRP1 mediated resistance.
Contrastingly, treatment of HEK293/MRP1 with SB743921 HCl elevated the resistance of
the cells against vincristine.
Table 2.4 Effect of selected hit compounds on the IC50 values of vincristine in
HEK293/MRP1 cells
a

Cell line/Treatment

IC50 (nM)
Vincristine

Fold
b

resistance

a

b

HEK293/pcDNA3.1

3.11 ± 0.23

1

HEK293/MRP1

62.25 ± 7.21

20.51

HEK293/MRP1 + MK571 [25 µM]

11.30 ± 1.00

3.64

HEK293/MRP1 + Amuvatinib [1µM]

28.42 ± 2.85

9.13

HEK293/MRP1 + TG101348 [1 µM]

22.26 ± 4.78

7.16

HEK293/MRP1 + SB743921 HCl [0.5 µM]

151.57 ± 20.75

48.78

Mean ± SEM of at least three independent experiments performed in triplicates.
Fold resistance determined by dividing the IC50 value for each treatment by the IC50

value of HEK293/pcDNA3.1 with vincristine alone.

70
4.0 Discussion
Recent advancement in chemotherapy has contributed to the improvement of survival rates
of several cancers. However, MDR has been a prime opponent to this treatment modality.
The occurrence of MDR in several carcinomas has limited the effectiveness of
chemotherapy. The efflux activity of overexpressed MRP1 in tumor cells has been a key
contributor to this phenomenon. The substrate family of MRP1 spans multiple drug classes,
this includes conventional chemotherapeutic drugs such as etoposide, doxorubicin,
paclitaxel among others [28]. It also affects the efficacy of antivirals, antibiotics,
antimalarials among others [23]. As such, the overexpression of MRP1 by tumor cells is
used as a survival and protection strategy to reduce the intracellular drug concentration and
accumulation of such drugs to render them less potent by reducing their bioavailability.
This goes a long way to reduce the cytotoxic effect of such drugs on cancer cells. This
phenomenon in cancer cells has led to the elevated risk of treatment failure, and decreased
survival rates of patients, thus pose a huge challenge to the pharmaceutical industry and
clinical oncology researchers.
Modulating the expression and function of MRP1 via biochemical modulation has become
one of the powerful tools used by cancer researchers to overcome MPR1-mediated MDR.
Biochemical modulation provides the platform for scientists to modulate the function and
the transport in tumor cells without perturbing physiological homeostasis in normal cells.
By using the biochemical modulation toolbox, two or more pharmacological agents that
may work via varying molecular mechanisms and may have different molecular targets can
be combined at their respective effective doses to achieve a common goal without eliciting
any unacceptable side effects. Based on this principle, an inhibitor of MRP1 can be

71
combined with another chemotherapeutic agent with superior potency against tumor cells
in one formulation. In this instance, the inhibitor can impede the efflux activity of MRP1
to ensure that the other anticancer drug is bioavailable to yield the desired response and
effect. Although some modulators of MRP1 have been identified in recent times,
challenges like non-specific toxicity, low multidrug reversal effects, and undesirable offtarget effects limit their effectiveness. Thus, there is the need to identify more potent, welltolerated modulators with significant MDR reversal effects and limited non-specific
toxicity.
In this present study, we successfully screened 30 drugs which consisted of both anticancer
and FDA drugs using an In-cell ELISA assay to identify modulators of MRP1 in HEK293
MRP1-overexpressing cells. We identified 7 hit compounds (drugs that modulated MRP1
protein expression above 50%) representing 23.33% of the total compound screened. Three
of the hit compounds; Epirubicin HCl, Felbamate, and Irinotecan increased the protein
expression of MRP1. Four of the hit compounds; Vismodegib (GDC-0449), TG101348
(SAR302503), Amuvatinib, and SB743921 HCl decreased MRP1 protein expression in
HEK293/MRP1 cells. Epirubicin HCl is an anthracycline that targets topoisomerase II [31].
Epirubicin HCl prevents DNA segregation and DNA synthesis by stabilizing the DNA –
topoisomerase complex [32-36]. This antineoplastic agent is used in the treatment of breast
cancer, and a known substrate of MRP1 [29]. Irinotecan is a derivative of Camptothecin
that elicits its antitumor activity by inhibiting topoisomerase I (a nuclear enzyme that
regulates the unwinding of DNA during replication) [37]. It is used in the treatment of
metastatic colorectal cancer [38-41] and has been reported to be a substrate of MRP1 [28].
Vismodegib is a recently approved FDA drug that inhibits the hedgehog signaling pathway
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[42]. This orally bioavailable small molecule is used in the treatment of locally advanced
and metastatic unresectable basal cell carcinoma (BCC) [42]. Vismodegib is among the
few small molecules that have been reported to inhibit the activity of MRP1 [30]. Since the
impact of Epirubicin HCl, Irinotecan, and Vismodegib on MRP1 have already been
reported in other studies, we focused on characterizing other hit compounds whose
modulatory effects on MRP1 had not been reported.
The novel drugs identified in our initial screening included; SB743921 HCl, Amuvatinib,
TG101348 (SAR302503), and Felbamate. Except for Felbamate; SB743921 HCl,
Amuvatinib, and TG101348 (SAR302503) based on their mode of action have been
reported to be ATP competitive inhibitors. ATP competitive inhibitors are inhibitors that
act by competing with ATP to block the activity of their targets [43]. These inhibitors are
also known as Type 1 inhibitors. SB743921 HCl is a novel kinesin spindle inhibitor that
elicits its function by impeding functional mitotic spindle formation in cell mitosis by
hydrolyzing ATP [44], thereby regulating cell division. SB743921 HCl has been reported
to show a strong inhibitory effect on ERK and AKT activity in chronic myeloid leukemia
(CML) cells [45]. Although SB743921 HCl has been reported to have a strong inhibitory
effect on tumor cells, its interaction with MRP1 as well as its effect on MRP1 activity and
expression is yet to be reported. Amuvatinib on the other hand is an orally bioavailable
small molecule that is reported to inhibit the activity of the MET receptor tyrosine kinase,
c-KIT, and platelet-derived growth factor receptor (PDGFR) by competing with ATP for
binding at the catalytic site [46]. This multi-targeted tyrosine inhibitor is currently in phase
II clinical trials for the treatment of solid tumors [47, 48]. A recent study in our lab group
that aimed at identifying novel inhibitors of MRP1 using a doxorubicin-based screening
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assay revealed that Amuvatinib may inhibit MRP1 activity, however, its impact on MRP1
protein expression as well as its ability to reverse MRP1 mediated resistance has never
been reported. TG101348 (SAR302503) is an orally bioavailable selective inhibitor of
Janus-associated kinase 2 [49-51]. It elicits its inhibitory effect by competing with JAK2
for ATP binding , this results in JAK2 inactivation and subsequent inactivation of the JAKSTAT pathway. Thereby inducing apoptosis in tumor cells. This ATP competitive inhibitor
of JAK2 was recently approved for the treatment of adult patients with intermediate-2 or
high-risk primary or secondary myelofibrosis in the United States, and it is currently in
phase III clinical trial for myelofibrosis treatment globally [49]. TG101348 (SAR302503)
has also been reported to enhance the cytotoxic effect of imatinib (a well-known drug for
the treatment) of Chronic myeloid leukemia (CML) in residual CML cells [52]. It is also
reported to impede growth of Hodgkin lymphoma and mediastinal large-cell lymphoma in
both in vitro and in vivo studies [53]. Despite the success of TG101348 (SAR302503) in
treatment of tumor cells, its interaction with MRP1 is yet to be reported.
In this study, we demonstrated using In-Cell ELISA assay that the ATP competitive
inhibitors; SB743921 HCl, Amuvatinib, TG101348 (SAR302503) significantly
downregulated the protein expression of MRP1 in HEK293 MRP1-overexpressing cells.
For the first time, we report that SB743921 HCl and Amuvatinib demonstrate a
concentration and time-dependent activity in modulating MRP1 protein expression with
greater significance observed at concentrations above 10 µM and incubation periods above
24 hours. We also showed that TG101348 (SAR302503) exhibited significant
downregulation of MRP1 protein expression at 10 µM and after 48 hours incubation
period. Felbamate, an antiepileptic FDA approved drug, was also reported for the first time
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to significantly increased the expression levels of MRP1 in HEK293 MRP1overexpressing cells in this study. Significant upregulation of MRP1 protein expression
was observed at concentrations above 10 µM and after 48 hours of incubation when cells
were treated with felbamate. Although these drugs modulated MRP1 protein expression,
further research must be conducted to evaluate if

SB743921 HCl, TG101348

(SAR302503) are inhibitors of MRP1 and whether Felbamate is a substrate of MRP1.
Moreover, further studies to determine the mechanism of interaction between these novel
modulators and MRP1 would be a step in the right direction. Nonetheless, it is possible to
speculate that SB743921 HCl may downregulate MRP1 protein expression by obstructing
the PI3/Akt signaling pathway. This is because the PI3/Akt signaling pathway has been
reported to modulate MRP1 expression in human acute myeloid leukemia [54], and
SB743921 HCl has also been reported to strongly inhibit this pathway [45]. However,
further studies are needed to verify the involvement of the PI3/Akt pathway in the
modulatory effect of SB746921 HCl on MRP1.
We also evaluated the effect of these novel modulators on MRP1 efflux activity using the
flow cytometry-based calcein accumulation assay. Our results demonstrate that SB743921
HCl, TG101348 (SAR302503) can strongly inhibit MRP1 mediated calcein efflux.
Amuvatinib which was previously reported to inhibit MRP1 mediated doxorubicin efflux
in small cell lung cancer cells (H69AR) [55], also inhibited MRP1 mediated calcein efflux
in HEK293 MRP1-overexpressing cells in this study. These results indicate that
Amuvatinib may be able to inhibit efflux of several substrates of MRP1, making it an
interesting therapeutic agent to explore in further studies. Contrastingly, we did not observe
any significant inhibition in MRP1-mediated calcein efflux when cells were treated with
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felbamate and compared to the no treatment control. This may be to the fact that the
presence of felbamate upregulates MRP1 protein expression in these cells, as such increase
the overall efflux of calcein as observed.
We also showed that the three novel modulators that decreased MRP1 protein expression
in this study are also able to inhibit the growth of HEK293 MRP1-overexpressing cells at
clinically achievable concentrations (Table 2.3). This observation may be in synchrony
with their ability to decrease MRP1 protein expression in these cells. Felbamate (average
IC50 – 47.23 µM) on the other hand, was the least potent in inhibiting the growth of
HEK293/MRP1 among the novel modulators identified. This may be because felbamate
increases MRP1 protein expression as observed earlier in this study, thus it is easily
effluxed by the transporter as such enhancing the survival of these cells and requiring a
higher dose of drug treatment to achieve the half-maximal inhibitory effect. However,
further research is needed to elucidate and verify the mode of interaction and action
between felbamate and MRP1.
One of the major limitations of current modulators of MRP1 is the inability of these
modulators to reverse MRP1-mediated resistance. Thus, we investigated the ability of our
identified novel modulators (SB743921 HCl, Amuvatinib, TG101348 (SAR302503)) to
reverse MRP1- mediated resistance against vincristine in HEK293 MRP1-overexpressing
cells. Amuvatinib and TG101348 (SAR302503) were most effective in reversing MRP1mediated resistance in HEK293 MRP1 overexpressing cells (Table 2.4). TG101348
(SAR302503) sensitized HEK293/MRP1 cells to the cytotoxic effects of vincristine,
thereby reducing the average IC50 from 62.25µM to 22.26 µM with a fold reduction from
20.51 to 7.16-fold resistance. Amuvatinib also reversed MRP1 mediated resistance towards
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vincristine by decreasing the average IC50 from 62.25µM to 228.42 µM with a fold
reduction from 20.51 to 9.13-fold resistance. Contrastingly, we observed that SB743921
HCl enhanced resistance of HEK293 MRP1-overexpressing cells towards vincristine. Our
results demonstrate that Amuvatinib and TG101348 (SAR302503) can reverse MRP1
mediated MDR in MRP1 overexpressing cells. It would be of interest to investigate the
ability of Amuvatinib, TG101348 (SAR302503) to reverse MDR mediated by MRP1 and
other ABC transporters in other cell lines.
Findings from this project indicate that the test compounds; SB743921 HCl, Amuvatinib,
and TG101348 (SAR302503) decreased MRP1 protein expression and its efflux activity,
with Amuvatinib and TG101348 (SAR302503) exhibiting high potency in reversing
MRP1-mediated MDR. Therefore these aforementioned drugs can be used in the
development of combinatorial drug therapy with an anticancer drug that is potent in
targeting and treating cancer cells but is a substrate of MRP1. As such in cancer cells
overexpressing the MRP1 transporter, administration of such formulations allow the
modulator to downregulate the MRP1 expression levels enabling the anticancer drug to
accumulate at the appropriate concentration and be bioavailable to elicit its desired effect.
These interventions would go a long way to aid in our fight against tumor chemoresistance
mediated by MRP1. Our novel modulator, Felbamate which increased MRP1 protein
expression in this study can also be used in the treatment of diseases whose etiology
involves the down-regulation of MRP1 expression levels. For instance, Alzheimer’s
disease is a neurodegenerative disorder that is pathologically characterized by the
accumulation of beta-amyloid peptide (Aß) in the brain of its patients [56]. Studies by
Krohn and his colleagues revealed that deficiency of MRP1/ABCC1 in mice models that
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expressed Swedish human Aß precursor protein (APPswe) and mutant presenilin-1 (PSI)
(APP/PSI mice x Abcc1-/-) resulted in elevated levels of cerebral beta-amyloid peptide
(Aß) but did not affect the expression levels of enzymes responsible for the production of
Aß from APP [57]. However, treatment with an MRP1 inducer, thiethylperazine resulted
in decreased Aß levels in APP/PS1 mice brains. These results demonstrated the role of
MRP1 in the clearance of Aß and its sequential accumulation in the brain. Thus in disease
states like Alzheimer’s disease, drugs with a high potency of inducing and increasing
MRP1 expression levels are desirable. Therefore, our novel modulator, Felbamate which
increased MRP1 protein expression in HEK293 MRP1 overexpressing cells in this study
and is currently used for the treatment of Epilepsy can be a good candidate for treating such
disorders. It would be a step in the right direction to investigate how Felbamate can be used
in targeting and treating disorders in which MRP1 expression levels are down-regulated.
In summary, we investigated the modulatory effect of a unique set of drugs on MRP1
protein expression. We identified four novel modulators of MRP1 protein expression in
HEK293 MRP1-overexpressing cells. We report for the first time that novel ATP
competitive

inhibitors;

SB743921

HCl,

Amuvatinib,

TG101348

(SAR302503)

downregulate MRP1 protein expression and activity. Findings from our work suggest that
the identified modulators may limit toxicity and increase the effectiveness of overcoming
MRP1 mediated MDR. Thus the drugs can be explored in combinatorial drug therapy
aimed at targeting tumors with the MDR phenotype conferred by MRP1 overexpression.
Drugs that showed little to low modulatory effect on MRP1 in our initial screening may
have a lower risk of being interfered by MRP1-mediated MDR.
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Chapter 3
Tie2 kinase and mTOR targeted agents modulate MRP1 activity in MRP1overexpressing cells
Abstract
Chemotherapy is the only systemic treatment for many cancers. Overexpression of MRP1
in cancer cells facilitates the efflux of administered chemotherapeutic drugs, thereby
reducing their intracellular drug concentration and bioavailability. This results in tumor
cells becoming unresponsive and resistant to therapeutic agents. The development of
multidrug resistance in cancer cells leads to increased risk of treatment failure and reduced
survival chances of cancer patients. Finding ways of regulating the activities of MRP1 in
overexpressed cells is of great pharmacological importance. We report that Tie2 kinase
inhibitor and mTOR inhibitor, Everolimus modulate MRP1 activity in MRP1overexpressing cells. Tie2 kinase inhibitor and Everolimus decreased MRP1 mediated
calcein efflux in HEK293 MRP1-overexpressing cells. However, these compounds did not
affect the protein expression of MRP1 in HEK293 MRP1-overexpressing cells. In
resistance reversal studies, Tie2 kinase inhibitor and Everolimus reversed MRP1-mediated
resistance towards vincristine in these cells. Overall, data from this study indicates Tie2
kinase inhibitor and Everolimus holds great potential for the development of therapeutics
targeting MRP1-mediated multidrug resistance.

Keywords: ABC transporters; multidrug resistance; MRP1; ABCC1; MRP1 modulators;
anticancer drug; drug profiling; drug-transporter interactions, Tie2, mTOR
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1) Tie2 Kinase Inhibitor (PubChem CID: 23625762); 2) Everolimus (PubChem CID:
6442177)
1.0 Introduction
Cancer is a global public health challenge with high morbidity and mortality. The potential
of tumor cells to develop resistance to mechanistically and structurally discrete
chemotherapeutic agents has become one of the major hindrances to the chemotherapy
regime. This phenomenon is described in clinical cancer research as Multidrug resistance
(MDR). The ATP binding cassette (ABC) transporters have been reported to be key players
in the MDR development of several carcinomas. This superfamily of transporters is
responsible for the efflux of a wide range of substrates in eukaryotes. These substrates
include xenobiotics, toxins, drugs, and their metabolites [1]. Due to the essential role
played by ABC transporters, cancer cells take advantage of their pivotal function to ensure
their survival against administered anticancer drugs. This they achieve by overexpressing
ABC transporters like P-glycoprotein (P-gp), Multidrug resistance protein 1 (MRP1), and
Breast cancer resistance protein (BCRP). As such administered chemotherapeutic drugs
are challenged by the efflux activity of these transporters as they serve as the first line of
defense in tumor cells. The removal of drugs and their metabolites by the overexpressed
ABC transporters across the plasma membrane has been associated with decreased
bioavailability and reduced therapeutic efficacy of anticancer drugs on tumor cells.
ABC transporters are a type of ATP-binding cassette pumps encoded by the ABC genes
[2]. This superfamily of transporters is grouped into seven subfamilies, subfamilies A-G in
humans. Most ABC transporters are characterized by a core unit consisting of membranespanning domains (MSDs) which consist of six hydrophobic α-helices, and nucleotide-
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binding domains (NBDs). The NBDs form the powerhouse of the transporter, as it is
responsible for ATP binding and hydrolysis for the generation of energy. The MSDs use
the energy generated to facilitate substrate recognition and substrate translocation across
the plasma membrane [3]. In recent times, the overexpression of the MRP1 transporter has
been associated with the development of MDR in several carcinomas including ovarian
cancer [4], childhood neuroblastoma, acute lymphoblastic leukemia[5]. MRP1 is a member
of the ABCC subfamily of ABC transporters. It is encoded by the gene ABCC1 [6]. MRP1
localizes at the basolateral membrane and is expressed in the epithelial cells of organs like
the adrenal gland, testes, kidney, gastrointestinal tract, and at pharmacological sacred sites
like the blood-brain barrier, blood-cerebrospinal fluid barrier, and the blood-testes barrier
[7, 8]. Substrates of MRP1 include; heavy metals, leukotrienes, prostaglandins, glutathione
(GSH), and glucuronide-conjugates of steroids [9, 10]. MRP1 also transports drugs from
various drug classes including; anthracyclines (doxorubicin), folate-based antimetabolites
(methotrexate), antivirals (saquinavir), antibiotics (difloxacin), plant alkaloids (etoposide,
paclitaxel) among others [11]. Due to the critical role MRP1 plays, and its ability to interact
with a wide range of drug families; its overexpression has been a destructive tool used by
cancer cells to efflux administered drugs out of the intracellular space in cancer patients
rendering these drugs less bioavailable to exert the desired effect. This phenomenon has
created a huge barrier to the effectiveness of chemotherapy and reduced survival rates of
cancer patients [12].
Finding ways of regulating the activities of MRP1 in overexpressed cells is of great
pharmacological essence. One approach is to curb this canker is to completely shut down
the efflux transporter, MRP1. Although this strategy may seem laudable; it would be
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suicidal for the cells as MRP1 is a key regulator of physiological homeostasis in cells.
MRP1 aids to maintain the GSH/GSSG (Oxide GSH) ratio to ensure redox homeostasis in
cells [13]. Moreover, the transport activity of MRP1 helps to prevent the accumulation of
toxicants and the buildup of estrogen-like compounds in the testes which aid to prevent
testicular feminization and protect developing spermatozoa [8, 14]. MRP1 also functions
to protect the heart by facilitating the efflux of toxic products of oxidative stress from the
mitochondria and cardiomyocytes [15]. From the aforementioned roles played by MRP1
in maintaining physiological balance in cells, the complete shutdown of the transporter
would cause significant perturbations in the physiological balance of cells. An alternative
approach that can be utilized to regulate the activity of the transport in tumor cells without
disturbing the physiological equilibrium, is to use the biochemical modulation toolbox.
Biochemical modulation involves the use of therapeutic agents including small molecules
to achieve selective manipulation of tumor cell metabolism or signal transduction pathways
to ensure the more selective response of tumor cells to the action of anticancer drugs [16].
The phosphoinositide 3 kinases/Akt (PI3K/Akt) signal transduction pathway has been
reported as one of the cellular pathways that regulate the expression levels of MRP1 [17,
18]. PI3K is a lipid kinase involved in the regulation of biological events such as migration,
metabolism, survival, and also activates a lot of downstream proteins [19]. Serine
(Ser)/Threonine (Thr) kinase also known as Akt or protein kinase B regulate the expression
and activity of numerous proteins including MRP1 [20, 21]. This pathway has been
reported to be involved in MDR observed in breast cancer, lung cancer. ovarian cancer,
melanoma, and hepatocellular carcinoma [18-23]. As such, this pathway offers a great
avenue for the development of novel strategies to target MRP1 in MDR. Moreover,
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exploring the impact of activators and downstream effectors of this pathway on MRP1
activity and expression would aid in identifying potential therapeutic targets for the
development of more efficacious and specific therapeutics for targeting MRP1 mediated
MDR and treating cancer patients [18]. Tunica interna endothelial cell (Tie2) tyrosine
kinase receptor is an endothelial cell-specific receptor which activates the PI3/Akt pathway
in normal endothelial cells [22]. It has been associated with the extravascular compartment
of several tumors such as inflammatory breast cancer, leukemia, gastric, and thyroid tumors
[23]. mTOR (mammalian target of rapamycin) on the other hand is a serine/threonine
kinase that modulates the diverse nutritional and environmental cues like amino acids,
growth factors, cellular stress among others in cells [24]. Moreover, mTOR is also reported
to function downstream the PI3K/Akt signaling pathway and has been involved in the
etiology of several cancers [24, 25]. In this study, we investigated the effect of a novel
inhibitor of Tie2 (Tie2 kinase inhibitor) and mTOR inhibitor (Everolimus) on MRP1
activity and protein expression in MRP1-overexpressing cells using established methods.
We also determined the ability of these drugs to reverse MRP1-mediated resistance in
MRP1-overexpressing cells.
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2.0 Materials and methods
2.1 Chemicals
Test compounds were procured from APExBIO Technology LLC (Houston, TX). MK571
was acquired from APExBIO Technology LLC (Houston, TX), thiazolyl blue tetrazolium
bromide (MTT) were procured from Sigma-Aldrich (St. Louis, MO).and Calcein
acetoxymethyl ester (Calcein-AM) was obtained from Corning Life Sciences (Corning,
NY).

2.2 Cell lines and cell culture
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD) respectively. Dulbecco’s modiﬁed Eagle medium
(DMEM) (GE Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine
serum (FBS) was used to grow the HEK293 cell lines. Cell lines were cultured in a
humidiﬁed incubator maintained at 5% CO2 and 37 °C. This incubation condition was
retained in all subsequent cell culture procedures.

2.3 Flow cytometry-based calcein accumulation assay
The effect of Tie2 kinase inhibitor and Everolimus on MRP1 mediated efflux of calceinAM was ascertained using flow cytometry. HEK293 MRP1-overexpressing cells were
prepared in serum-free medium at a cell density of 7 × 105 cells/ml and treated with 10
µM of test compounds for 10 minutes at 37 °C. Cells were then treated with calcein-AM
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(0.25 µM) for 30 minutes. Final DMSO concentration was maintained at 0.1% (v/v). MRP1
mediated efflux activity was stopped using ice-cold PBS buffer (3 ml). Cells were
collected, washed twice with PBS, and resuspended in a cold PBS buffer containing 1%
paraformaldehyde. Intracellular calcein-AM fluorescence was detected using BD Accuri
C6 flow cytometer ( BD Biosciences, San Jose, CA) with excitation and emission at 480
nm and 533/30 nm respectively. Fluorescent intensity was determined as a mean of 10000
events. Treatments were done in duplicates and experiments were performed in three
independent studies.

2.4 Determination of concentration-dependent activity on MRP1 protein expression
using western blot assay.
HEK293/MRP1 and HEK239/pcDNA 3.1 (parental control) cells were seeded at 7x105
cells per well in 6-well plates with DMEM containing 10% FBS and incubated for 24
hours. Cells were treated with varying concentrations of drugs; 5 µM, 10 uM, 20 µM, and
0.1% DMSO for controls, and incubated for 48 hours at 37 °C. At the end of the incubation
period, the spent media was removed and cells were rinsed with 1000 μl of PBS. The cells
were lysed with lysis buffer containing radioimmunoprecipitation assay buffer (RIPA
Buffer, Thermo Fisher Scientific, Waltham, MA) supplemented with 1× halt protease
inhibitor cocktail (to inhibit the activity of cell proteases). Protein concentration was
determined with the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific,
Waltham, MA) using bovine serum albumin as standard. Proteins (20 μg) were loaded in
each well and sodium dodecyl sulfate (SDS) page electrophoresis was conducted on 8.0%
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mini SDS gels, after which proteins were transferred to Immobilon PVDF membranes
(EMD Millipore, Burlington, MA) for 4 hours. The membrane was blocked with 5%
bovine serum albumin (BSA) in Tris Buffered Saline -Tween 20 (TBS-T,0.1%), and
washed with TBS-T (0.1%; 3× per 10mins). Followed by incubation (4 °C, overnight) with
monoclonal MRP1 antibody [EPR21062](ab233383) and anti-GAPDH antibody (Thermo
Fisher Scientific, AM4300) dissolved in TBS-T (0.1%) with BSA (1%) at 1:250 and
1:1000 dilutions respectively. The membrane was washed with TBS-T (0.1%, 3× per
10mins) and incubated with secondary antibody using horseradish peroxidase-conjugated
goat anti-mouse IgG(H+L) (Thermo Fisher Scientific) for alpha-tubulin detection, and
horseradish peroxidase-conjugated goat-anti-rabbit IgG(H+L) (Thermo Fisher, Scientific)
for MRP1 detection. Target proteins were detected using Western blotting luminol reagent
(Santa Cruz Biotechnology, sc-2048). Signals were quantified using Image Studio Lite
version 5.2 and normalized by using the intensity of the corresponding protein band relative
to the GAPDH band.

2.5 In vitro cytotoxicity assay
The cytotoxicity effect of the test compounds was investigated by using the MTT
colorimetric assay. HEK293/MRP1 and HEK293/pcDNA3.1 cells were seeded in 96 well
plates at a cell density of 5 ×103 per 100 ul of culture medium and incubated overnight.
Cells were treated with varying concentrations of the test compound diluted in medium and
were incubated for 72 hours. At the end of the incubation period, 100 ul of spent media
was carefully decanted. MTT (0.5 mg/ml) treatment was conducted for 4 hours. Dissolution
of formazan crystals was done by the addition of 100 ul of 15% SDS containing 10 mM
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HCl, absorbance was read at 570 nm using a Hidex Sense Beta Plus plate reader (Turku,
Finland). Treatments were performed in triplicates and repeated in two independent
experiments.

2.6 MDR reversal activity of test compounds
Reversal of resistance effect of Tie2 kinase inhibitor and Everolimus was determined using
MTT assay. Cells were seeded at a cell density of 5×103 per 100 ul of culture medium in
96 well plates and incubated for 24 hours at 37°C to allow cells to attach. Drug treatment
was then conducted by treating cells with 150 ul of test compounds at selected noncytotoxic concentrations. The addition of varying concentrations of vincristine (50 µl) was
conducted after an hour. MTT treatment (0.5 mg/ml) was conducted for 4 hours. The
formazan crystals were dissolved by the addition of 100 ul of 15% SDS containing 10 mM
HCl and absorbance at 570 nm was recorded using a Hidex Sense Beta Plus plate reader
(Turku, Finland). Treatments were done in triplicates, and experiments were performed in
two independent studies.

2.7 Statistical Analysis
Statistical analysis was performed using GraphPad Prism TM software (GraphPad
Software version 8.4.3, San Diego, CA, USA). The differences between mean values were
analyzed using linear mixed model analysis. Sidak correction was applied for multiple
comparisons, statistical testing was performed at a 5% level of significance.
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3.0 Results
3.1 Effect of test compounds on MRP1 efflux activity
Calcein-AM is a common substrate of MRP1 and is widely used to study MRP1 mediated
efflux. When the acetoxymethyl ester (AM) moiety of calcein is cleaved by esterases in
cells, calcein becomes fluorescent. The impact of MRP1 efflux activity was investigated
using flow cytometry. The structures of Tie2 kinase inhibitor and Everolimus are shown in
Figure 3.1. As shown in Figure 3.2, HEK293 MRP1-overexpressing cells in the absence of
MK571 showed very low retention of calcein whilst in the presence of MK571 (25µM),
the accumulation of calcein strongly increased by 3.85 fold . HEK293/MRP1 cells in the
presence of Tie2 kinase inhibitor and Everolimus also increased the accumulation of
calcein in the cells approximately by 3.96-fold and 3.83-fold respectively. The fold
increase in calcein accumulation in the presence of the test compounds was very
comparable to the positive inhibitor, MK571. This finding suggests that Tie2 kinase
inhibitor and Everolimus may decrease MRP1 efflux activity leading to the increase in
calcein observed.

Tie2 Kinase Inhibitor
Figure 3. 1 Chemical structures of test compounds

Everolimus

96

Figure 3.2 Effect of test compounds on MRP1 efflux activity.
HEK293/MRP1 cells were treated with 10 µM of the test compounds and 25 µM of MK571
(positive control) for 10 minutes at 37 °C before treatment with 0.25 µM calcein-AM for
an hour, Flow cytometric measurements of intracellular calcein-AM was conducted at 488
nm and 533/30 nm for excitation and emission wavelengths, respectively. Experiments
were done as duplicates in three independent experiments and presented as mean ± S.E.M.
Data was analyzed using a linear mixed model and Sidak post hoc test. *P < 0.05; **P <
0.01; ***P < 0.001 ; ****P < 0.0001 compared to control.
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3.2 Effect of test compounds on MRP1 protein expression levels
To determine the influence of Tie2 kinase inhibitor and Everolimus on MRP1 protein
expression, we conducted a western blot assay using varying concentrations of the test
compounds (5 µM, 10 µM, 20 µM) (Figure 3.3A). The protein expression levels of MRP1
was not significantly impacted when HEK293 MRP1-overexpressing MRP1were treated
with 5 µM, 10 µM, and 20 µM of test compounds and compared to the protein expression
levels of the control (Figure 3.3B).

[A]
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[B]

Figure 3.3 Effect of test compounds on MRP1 protein expression.
[A] Shown are representative western blots of whole-cell lysates (20ug of protein/lane)
prepared from HEK293/pcDNA3.1 and HEK293/MRP1 cells treated with varying
concentrations of test compounds (5 µM, 10 µM, 20 µM), and 0.2% DMSO (controls) for
48 hours. MRP1 proteins were detected with monoclonal anti MRP1 antibody
[EPR21062](ab233383, Abcam) and anti-GAPDH antibody (Sigma-Aldrich) at a dilution
of 1:250 and 1:1000 respectively. Secondary antibodies; mAb - anti-rabbit and mAb-antigoat were used at a dilution of 1:1000. Whole cell lysates were run on 8% SDS gel for one
hour before being transferred to the pretreated PVDF membrane. Three independent
experiments were conducted, and data presented as mean ± S.E.M. [B] Protein band density
was analyzed using the Image Studio Lite (LI-COR Biotechnology) software and corrected
for uneven sample loading and transfer using GAPDH as the loading control. Data was
analyzed using a linear mixed model and Sidak post hoc test.
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3.3 Impact of test compounds on MRP1-mediated resistance
Although recent advancement in chemotherapy has resulted in improved survival rates of
cancer patients, multidrug resistance (MDR) in tumor cells possess a great limitation on its
success. Thus, we investigated the ability of Tie2 kinase inhibitor and Everolimus to
reverse MRP1 mediated resistance towards vincristine. Vincristine is a commonly used
anticancer drug, that is used in the treatment of several carcinomas. Unfortunately, MRP1
is reported to mediate the resistance of tumor cells to vincristine. As presented in Figure
3.4, HEK293 MRP1-overexpressing in the absence of MRP1 (solid red) demonstrated very
high resistance to vincristine cytotoxic effect giving a fold resistance of 19.96 folds (Table
3.1). The parental cell line HEK293/pcDNA3.1(dotted blue) which does not overexpress
MRP1 showed low resistance to vincristine (Figure 3.4). In the presence of MK571 (25
µM), HEK293/MRP1 cells became more sensitive to the cytotoxic effect of MK571
resulting in reducing the fold resistance observed in these cells to 3.75 fold resistance
(Table 3.1). Our test compounds also reversed MRP1 mediated resistance towards
vincristine in HEK293/MRP1 cells. Everolimus (dotted purple) and Tie2 kinase inhibitor
(dotted orange) decreased vincristine resistance to 7.01-fold resistance and 8.91-fold
resistance respectively (Figure 3.4, Table 3.1).
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Figure 3.4 Effect of Tie2 kinase inhibitor and Everolimus on drug sensitivity of
HEK293 MRP1-overexpressing cells towards vincristine.
Cells were treated with increasing concentrations of vincristine in the absence or presence
of a non-cytotoxic concentration of test compounds. MK571 (25 µM) served as the positive
control. MTT assay was conducted to determine cell viability after 72 hours. Data is
representative of three independent experiments and expressed as mean ± SEM.
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Table 3.1 Effect of selected Tie2 Kinase Inhibitor and Everolimus on the IC50 values
of vincristine in HEK293/MRP1 cells
Cell line/Treatment

IC50a (nM)
Vincristine

Fold resistanceb

HEK293/pcDNA3.1

3.11 ± 0.23

1.00

HEK293/MRP1

62.02 ± 4.33

19.96

HEK293/MRP1 + MK571 [25 µM]

11.65 ± 1.79

3.75

HEK293/MRP1 + Everolimus [5 µM]

21.78 ± 3.34

7.01

HEK293/MRP1 + Tie2 Kinase Inhibitor [1] µM

27.67 ± 1.09

8.91

a
b

Mean ± SEM of at least three independent experiments performed in triplicates.

Fold resistance determined by dividing the IC50 value for each treatment by the IC50
value of HEK293/pcDNA3.1 with vincristine alone.
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4.0 Discussion
Chemotherapy is the standard treatment for systemic cancer in both metastatic and locally
advanced carcinomas. Although chemotherapy has been beneficial for treating cancer,
patients perpetually experience recurrence after therapy and exhibit a multidrug-resistant
phenotype [26]. The development of the multidrug-resistant phenotype in tumor cells is
resulted in tumor cells becoming unresponsive and insensitive to a variety of
chemotherapeutic agents [27]. This phenomenon is termed Multidrug resistance (MDR).
MDR has become one of the major challenges to the success of chemotherapy. The
overexpression of ABC transporters like MRP1 has been associated with the development
of MDR in tumor cells. MRP1 like other ABC efflux transporters utilizes energy from ATP
hydrolysis to facilitate the efflux of its substrate across biological membranes.
Overexpression of MRP1 has been associated with increased drug efflux resulting in
reduced intracellular effective drug concentration of a wide range of anticancer agents
(doxorubicin, vincristine, methotrexate), thereby contributing to MDR and elevated
chemotherapeutic failure [17, 28]. Recent studies have aimed at identifying novel strategies
to modulate the structure and function of MRP1 in order to regulate its activity in the MDR
of tumor cells. Some modulators like MK571, ONO-1078, probenecid, indomethacin have
been identified in recent times [29], yet some dreadful side effects and elevated patient
toxicities due to these modulators have limited the possibility of translating these promising
therapeutics from the bench side to the clinic. Thus there is the need for more potent and
safer MRP1 modulators.
Regulating effectors of signaling pathways that have been reported to be associated with
MDR can aid discover new and ideal strategies for developing targeted therapeutics for
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MRP1-mediated MDR. In this study, we successfully explored the effect of novel Tie2
kinase inhibitor and mTOR inhibitor, Everolimus, on MRP1 activity and expression in
HEK293 MRP1-overexpressing cells. To the best of our knowledge there no evidence
indicating the interaction between Tie2 kinase inhibitor and MRP1. Thus we report for the
first time that Tie2 kinase inhibitor downregulates MRP1 mediated calcein efflux in
HEK293 MRP1- overexpressing cells. Tie2 kinase inhibitor is an optimized compound of
SB203580 which is highly selective for the Tie2 tyrosine kinase receptor [30]. Tie2 kinase
inhibitor is reported to show inhibitory activity against Tie2 and also inhibit angiogenesis
in MOPC-315 plasmacytoma xenograft model [30]. Tie2 tyrosine kinase receptor is also
known as angiopoietin-1 receptor or Tek. The Ang-Tie2 system is reported to play roles in
endothelial cell survival and proliferation, vascular plasticity, and angiogenesis [31]. It is
also reported to activate the Akt in the P13/Akt signaling pathway which is known to
modulate the activity of MRP1 expression and activity. Tie2 has been implicated in several
tumors [23]. For instance, studies by Martin et al. showed that Tie2 signaling is associated
with MDR in human glioma cells by upregulating ABC transporters [23]. Thus the
downregulation of MRP1 efflux activity by Tie2 kinase inhibitor observed in this present
study may be mediated via disruption of the Tie2 signaling pathway and subsequent
deactivation of the PI3/Akt pathway signaling. However, it will be of great interest to
ascertain the mechanism of action and interaction of the Tie2 kinase inhibitor and the
MRP1 inhibitor. In addition to downregulating the MRP1 efflux activity, Tie2 kinase
inhibitor also strongly reversed MRP1- mediated resistance in HEK293 MRP1overexpressing cells. Treatment of cells with Tie2 kinase inhibitor reversed resistance
against vincristine by decrease the average IC50 from 62.02 µM (vincristine only treatment)
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to 27.67 µM with the corresponding reduction in fold resistance from 19.96-fold resistance
to 8.91-fold resistance. As such, Tie2 kinase inhibitor may be a potent candidate for
modulating MRP1 mediated chemoresistance in tumor cells. Treatment of HEK293
MRP1-overexpressing cells with 5 µM, 10 µM, 20 µM of Tie2 kinase inhibitor did not
yield any significant alteration on MRP1 expression in this cell line. Studies by Martin and
his colleagues also reported that Tie2 upregulation did not have any significant impact on
mRNA levels of MRP1/ABCC1 in human glioma cells [26]. Thus considering our results
from this study and the observation reported from the previous study [26], modulation of
Tie2 signaling may affect MRP1 activity but not modulate its expression levels. However,
it would be enlightening to investigate the effect of Tie2 kinase inhibitor on MRP1
expression levels in other cell lines. Findings from this study suggest that the Tie2 kinase
receptor may be a potential molecular target for the development of efficacious and specific
therapeutics for targeting and treating MRP1 mediated MDR.
The use of Rapamycin and rapalogs (inhibitors of mTOR) have proven promising clinical
efficacy in chemotherapy. In this study, we demonstrated that rapamycin analog,
Everolimus down-regulates the MRP1 mediated calcein efflux in HEK293 MRP1overexpressing cells. Everolimus elicits its function by binding to cyclophilin, FKBP-12
which in turn binds to mTOR and forms the mTORC1 complex when it is associated with
raptor and MLST8 and inhibits downstream signaling [32]. mTORC1 complex is
implicated in the regulation and ordination of cell cycle progression, growth, and
metabolism [33-37]. mTORC1 is a downstream effector of the PI3/Akt pathway which has
been reported to modulate ABC transporters including MRP1. Thus Everolimus may elicit
its effect on MRP1 by modulating this pathway. In this present study, we demonstrate that
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Everolimus can also reverse MRP1 mediated calcein efflux in HEK293 MRP1overexpressing cells. Everolimus in this present study successfully decreased the fold
resistance of HEK293 MRP1-overexpressing cells towards vincristine from 19.96-fold
resistance to 8.91-fold resistance. Although Everolimus has been previously reported to
downregulate MRP1 expression levels in cisplatin-resistant gastric cancer cell line [38],
treatment of HEK293 MRP1-overexpressing cells with 5 µM, 10 µM, 20 µM of
Everolimus did not significantly alter protein expression levels in this study. It is not
uncommon to observe cell line-specific effects of a drug, moreover, the HEK293 MRP1overexpressing cells were generated by transfection as such these cells can possess very
different membrane dynamics and molecular profiles.
In summary, we successfully demonstrated the effect of novel Tie2 kinase inhibitor and
mTOR inhibitor, Everolimus, on MRP1 activity and expression on HEK293 MRP1overexpressing cells. We showed that these drugs downregulate MRP1 activity and can
reverse MRP1-mediated resistance. Thus these therapeutic agents are good candidates for
developing combinatorial therapeutic strategies for the modulation of MRP1 mediated
tumor chemoresistance.

106

REFERENCES
[1] M. Videira, R.L. Reis, M.A. Brito, Deconstructing breast cancer cell biology and the
mechanisms of multidrug resistance, Biochimica et Biophysica Acta (BBA)-Reviews on
Cancer 1846(2) (2014) 312-325.
[2] P.J. Verrier, D. Bird, B. Burla, E. Dassa, C. Forestier, M. Geisler, M. Klein, Ü.
Kolukisaoglu, Y. Lee, E. Martinoia, Plant ABC proteins–a unified nomenclature and
updated inventory, Trends in plant science 13(4) (2008) 151-159.
[3] V. Vasiliou, K. Vasiliou, D.W. Nebert, Human ATP-binding cassette (ABC) transporter
family, Human genomics 3(3) (2009) 1-10.
[4] X. Tong, J. Zhao, Y. Zhang, P. Mu, X. Wang, Expression levels of MRP1, GST-π, and
GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of
patients, Oncology letters 18(1) (2019) 22-28.
[5] J.A. El-Sharnouby, A.M. Abou El-Enein, D.M. El Ghannam, M.R. El-Shanshory, A.A.
Hagag, S. Yahia, R. Elashry, Expression of lung resistance protein and multidrug
resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia, Journal of
Oncology Pharmacy Practice 16(3) (2010) 179-188.
[6] S.P. Cole, K.E. Sparks, K. Fraser, D.W. Loe, C.E. Grant, G.M. Wilson, R.G. Deeley,
Pharmacological characterization of multidrug resistant MRP-transfected human tumor
cells, Cancer research 54(22) (1994) 5902-5910.
[7] M.J. Flens, G. Zaman, P. van der Valk, M.A. Izquierdo, A.B. Schroeijers, G.L.
Scheffer, P. Van Der Groep, M. de Haas, C. Meijer, R.J. Scheper, Tissue distribution of
the multidrug resistance protein, The American journal of pathology 148(4) (1996) 1237.

107
[8] J. Wijnholds, G.L. Scheffer, M. van der Valk, P. van der Valk, J.H. Beijnen, R.J.
Scheper, P. Borst, Multidrug resistance protein 1 protects the oropharyngeal mucosal layer
and the testicular tubules against drug-induced damage, The Journal of experimental
medicine 188(5) (1998) 797-808.
[9] R.G. Deeley, C. Westlake, S.P. Cole, Transmembrane transport of endo-and
xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins,
Physiological reviews 86(3) (2006) 849-899.
[10] S.P. Cole, Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present,
and future, Annu Rev Pharmacol Toxicol 54 (2014) 95-117.
[11] M. Munoz, M. Henderson, M. Haber, M. Norris, Role of the MRP1/ABCC1 multidrug
transporter protein in cancer, IUBMB life 59(12) (2007) 752-757.
[12] W. Greaves, L. Xiao, B. Sanchez-Espiridion, K. Kunkalla, K.S. Dave, C.S. Liang,
R.R. Singh, A. Younes, L.J. Medeiros, F. Vega, Detection of ABCC1 expression in
classical Hodgkin lymphoma is associated with increased risk of treatment failure using
standard chemotherapy protocols, Journal of hematology & oncology 5(1) (2012) 47.
[13] M.T. Kuo, Redox regulation of multidrug resistance in cancer chemotherapy:
molecular mechanisms and therapeutic opportunities, Antioxidants & redox signaling
11(1) (2009) 99-133.
[14] T.E. Tribull, R.H. Bruner, L.J. Bain, The multidrug resistance-associated protein 1
transports methoxychlor and protects the seminiferous epithelium from injury, Toxicology
letters 142(1-2) (2003) 61-70.

108
[15] P. Jungsuwadee, R. Nithipongvanitch, Y. Chen, T.D. Oberley, D.A. Butterfield,
D.K.S. Clair, M. Vore, Mrp1 localization and function in cardiac mitochondria after
doxorubicin, Molecular pharmacology 75(5) (2009) 1117-1126.
[16] A. Bloch, Metabolic conditioning and metabolic actuation: experimental approaches
to cancer chemotherapy involving combinations of metabolites and antimetabolites,
Cancer chemotherapy reports 58(4) (1974) 471-477.
[17] J.T. Lee, L.S. Steelman, J.A. McCubrey, Phosphatidylinositol 3′-kinase activation
leads to multidrug resistance protein-1 expression and subsequent chemoresistance in
advanced prostate cancer cells, Cancer Research 64(22) (2004) 8397-8404.
[18] P. Tazzari, A. Cappellini, F. Ricci, C. Evangelisti, V. Papa, T. Grafone, G. Martinelli,
R. Conte, L. Cocco, J. McCubrey, Multidrug resistance-associated protein 1 expression is
under the control of the phosphoinositide 3 kinase/Akt signal transduction network in
human acute myelogenous leukemia blasts, Leukemia 21(3) (2007) 427-438.
[19] J.A. Engelman, J. Luo, L.C. Cantley, The evolution of phosphatidylinositol 3-kinases
as regulators of growth and metabolism, Nature Reviews Genetics 7(8) (2006) 606-619.
[20] L. Li, X. Wei, Y. Pan, H. Li, H. Yang, Q. He, Y. Pang, Y. Shan, F. Xiong, G. Shao,
LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux
and activating PI3K/AKT signaling, Oncogene 29(43) (2010) 5785-5795.
[21] H. Wang, X.-H. Jia, J.-R. Chen, Y.-J. Yi, J.-Y. Wang, Y.-J. Li, S.-Y. Xie, HOXB4
knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM
cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling
pathway, International Journal of Oncology 49(6) (2016) 2529-2537.

109
[22] R. Harfouche, H.M. Hasséssian, Y. Guo, V. Faivre, C.B. Srikant, G.D. Yancopoulos,
S.N. Hussain, Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on
endothelial cells, Microvascular research 64(1) (2002) 135-147.
[23] V. Martin, D. Liu, J. Fueyo, C. Gomez-Manzano, Tie2, a journey from normal
angiogenesis to cancer and beyond, Histology and histopathology (2008).
[24] R. Zoncu, A. Efeyan, D.M. Sabatini, mTOR: from growth signal integration to cancer,
diabetes and ageing, Nature reviews Molecular cell biology 12(1) (2011) 21-35.
[25] R. Yuan, A. Kay, W.J. Berg, D. Lebwohl, Targeting tumorigenesis: development and
use of mTOR inhibitors in cancer therapy, Journal of hematology & oncology 2(1) (2009)
45.
[26] V. Martin, J. Xu, S. Pabbisetty, M. Alonso, D. Liu, O. Lee, J. Gumin, K.P. Bhat, H.
Colman, F. Lang, Tie2-mediated multidrug resistance in malignant gliomas is associated
with upregulation of ABC transporters, Oncogene 28(24) (2009) 2358-2363.
[27] B. Tan, D. Piwnica-Worms, L. Ratner, Multidrug resistance transporters and
modulation, Current opinion in oncology 12(5) (2000) 450-458.
[28] V. Ling, Multidrug resistance: molecular mechanisms and clinical relevance, Cancer
chemotherapy and pharmacology 40(1) (1997) S3-S8.
[29] P. Gupta, M. Xie, S. Narayanan, Y.J. Wang, X.Q. Wang, T. Yuan, Z. Wang, D.H.
Yang, Z.S. Chen, GSK1904529A, a potent IGF‐IR inhibitor, reverses MRP1‐mediated
multidrug resistance, Journal of cellular biochemistry 118(10) (2017) 3260-3267.
[30] M. Semones, Y. Feng, N. Johnson, J.L. Adams, J. Winkler, M. Hansbury,
Pyridinylimidazole inhibitors of Tie2 kinase, Bioorganic & medicinal chemistry letters
17(17) (2007) 4756-4760.

110
[31] H. Huang, A. Bhat, G. Woodnutt, R. Lappe, Targeting the ANGPT–TIE2 pathway in
malignancy, Nature Reviews Cancer 10(8) (2010) 575-585.
[32] P.J. Houghton, Everolimus, Clinical cancer research 16(5) (2010) 1368-1372.
[33] M.-A. Bjornsti, P.J. Houghton, The TOR pathway: a target for cancer therapy, Nature
Reviews Cancer 4(5) (2004) 335-348.
[34] Z. Feng, H. Zhang, A.J. Levine, S. Jin, The coordinate regulation of the p53 and
mTOR pathways in cells, Proceedings of the National Academy of Sciences 102(23)
(2005) 8204-8209.
[35] D.D. Sarbassov, S.M. Ali, D.M. Sabatini, Growing roles for the mTOR pathway,
Current opinion in cell biology 17(6) (2005) 596-603.
[36] R.J. Shaw, N. Bardeesy, B.D. Manning, L. Lopez, M. Kosmatka, R.A. DePinho, L.C.
Cantley, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer cell
6(1) (2004) 91-99.
[37] S. Wullschleger, R. Loewith, M.N. Hall, TOR signaling in growth and metabolism,
Cell 124(3) (2006) 471-484.
[38] L. Ying, Z. Zu-an, L. Qing-hua, K. Qing-yan, L. Lei, C. Tao, W. Yong-ping, RAD001
can reverse drug resistance of SGC7901/DDP cells, Tumor Biology 35(9) (2014) 91719177.

111

Chapter 4
Identification of FDA approved drugs as modulators of Multidrug Resistance Protein
2 (MRP2/ABCC2) expression levels in MRP2-overexpressing cells
Abstract
Multidrug Resistance Protein 2 (MRP2) is an ATP-dependent transmembrane protein that
plays a pivotal role in the efflux of a wide variety of physiological substrates across the
plasma membrane. Several studies have shown that MRP2 can significantly affect the
absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles of many
therapeutic drugs as well as chemicals found in the environment and diet. This transporter
can also efflux newly developed anticancer agents that target specific signaling pathways
and are major clinical markers associated with multidrug resistance (MDR) of several types
of cancers. MDR remains a major limitation to the advancement of the combinatorial
chemotherapy regimen in cancer treatment. In addition to anticancer agents, MRP2 also
reduces the efficacy of various drug classes such as antivirals, antimalarials, and
antibiotics. The unique role of MRP2 and its contribution to MDR makes it essential to
profile drug-transporter interactions for all new and promising drugs. Thus, this current
research seeks to identify modulators of MRP2 expression levels using cell-based assays.
A unique recently-approved FDA library (372 drugs) was screened using a high throughput
In-Cell ELISA assay to determine the effect of these therapeutic agents on protein
expression levels of MRP2. A total of 49 FDA drugs altered MRP2 expression levels by
more than 50% representing 13.17% of the compounds screened. Among the identified
hits, fifty-four (54) drugs increased expression levels whereas 12 drugs lowered expression
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levels of MRP2 after drug treatment. Our findings from this initial screening showed that
modulators of MRP2 peregrinates multiple drug families, and signifies the importance of
profiling drug interactions with this transporter. Data from this project provides essential
information to improve combinatorial drug therapy and precision medicine as well as
reduce drug toxicity of various cancer chemotherapies.

Keywords: ABC transporters; multidrug resistance; MRP2; ABCC2; MRP2 modulators;
FDA approved drug; In-Cell ELISA; drug profiling; drug-transporter interactions
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1.0 Introduction
MRP2 (ABCC2) is a member of the ATP-binding cassette superfamily of transporters,
MRP1 and MRP2 are homologous members of this superfamily [1]. In humans, it is
encoded by the gene ABCC2 [2]. Structurally, MRP2 is a 190-kDa membrane protein
consisting of 1545 amino acids. The predicted membrane topology consists of 17
transmembrane spanning domains (MSD0, MSD1, MSD2) which are linked together by
conserved linker regions, and two highly conserved nucleotide-binding domains (NBD1
and NBD2) that serve as substrate – binding sites [3] as shown in Figure 4.1.

Figure 4.1: The full-length model of the MRP2 protein
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Whilst MRP1 localizes at the basolateral membrane of endothelial cells, MRP2 localizes
at the apical membrane of polarized cells of hepatocytes, renal proximal tubular cells,
enterocytes, and syncytiotrophoblasts of the placenta [4]. It is known to play critical roles
in the export of conjugated bile salts in the liver as well as transport of physiological
important substrates such as glutathione-S-conjugates, 17-beta-glucuronsyl estradiol,
leukotriene C4 [5]. Overexpression of MRP2 is associated with multidrug resistance of
tumor cells such as hepatocellular, ovarian, colorectal, lung, breast, and gastric carcinomas
[6], where it pumps drug conjugates and drug complexes across the plasma membrane into
the extracellular space [5]. Thus affecting the bioavailability and efficacy of anticancer
drugs like cisplatin and methotrexate. Aside cancer drugs, MRP2 also affects the efficacy
of a broad spectrum of drug classes including HIV drugs (lopinavir), antibiotics(ampicillin,
azithromycin), and antihypertensives(Olmesartan, Temocaprilate) [7]. With MDR being a
major impediment to the chemotherapy regime and the overexpression of the MRP2
transporter being a major factor in this phenomenon, it is of great clinical interest to find
ways of addressing this canker. Two main approaches have been proposed by researchers.
One of which, is to completely block the efflux or pump activity of the transporter in these
cells [8]. However, this approach would be destructive to the cells since it may also impede
some important physiological activities of the transporter, thereby jeopardizing the overall
wellbeing and physiological homeostasis of the cell or tissue. Another possible approach
that was proposed, was to modulate the activity of this transporter using biochemical
modulation. Using biochemical modulation, exogenously supplied metabolites can be used
to selectively manipulate the activity of MRP2 in tumor cells to ensure the more selective
response of cancer cells to the action of administered anticancer agents [9]. This would go
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a long way to improve the bioavailability and efficacy of anticancer drugs in tumor cells.
Hence the identification of possible modulators of the MRP2 transporter is of great clinical
importance [8]. Moreover, the broad impact of the efflux activity of this transporter on the
efficacy of a broad class of drugs makes it essential to investigate the possible interactions
between various therapeutic drugs (both approved and those in clinical trials) and this
transporter. Thus in this study, a unique set of drugs from the FDA approved drug library
was screened using In-Cell ELISA to identify modulators of MRP2.
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2.0 Materials and methods
2.1 Chemicals
FDA( Food and Drug Administration) approved drug library was procured from Selleck
chemicals

(Houston,

TX).

Super

signal

West

Dura®

Extended

Duration

chemiluminescence substrate (21EAPI34076) was obtained from Thermo Fisher Scientific
(Waltham, MA).
2.2 Cell lines and cell culture
MDCKII, MDCKII/MRP2 cells were kindly provided by Dr. Alfred Schinkel (Netherlands
Cancer Institute, Amsterdam, The Netherlands). MDCKII cell lines were grown in
Dulbecco’s modiﬁed Eagle medium (DMEM) (GE Healthcare, Marlborough, MA, USA)
enriched with 10% fetal bovine serum (FBS). Cell lines were cultured in a humidiﬁed
incubator maintained at 5% CO2 and 37 ◦C. This incubation condition was retained in all
subsequent cell culture procedures.

2.3 Screening of FDA approved drug library using

In-Cell ELISA assay in

MDCKII/MRP2 cells
In-Cell ELISA assay development and optimization were performed with MDCKII and
MDCKII/MPR2 cells and used to screen the FDA approved drug library for modulators of
MRP2 protein expression. MDCKII/MRP2 cells were seeded at 7x104 cells per well in 96well plates with Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal
bovine serum and incubated for 24 hours. Cells were then treated with drugs (10 uM), and
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0.1% DMSO (control and Parental) and incubated for 48 hours at 37°C. At the end of the
incubation period, treatment was removed and cells were rinsed twice with 150 μl of PBS.
Cells were fixed with 3.7% paraformaldehyde and permeabilized with Triton-X 100. The
cells were blocked using fish gel (MB-066-0100, Rockland) and incubated overnight at 4
°C with monoclonal anti-MRP2 antibody (MABN1545, EMD Millipore) or anti-α tubulin
antibody (T5168, Sigma-Aldrich) in a 1:1000 dilution. Secondary antibody incubation was
performed using horseradish peroxidase-conjugated goat anti-mouse IgG (H + L) (Thermo
Fisher Scientific, Waltham, MA) for an hour at room temperature. Target proteins were
detected using Super signal West Dura® Extended Duration Substrate chemiluminescence
substrate (21EAPI34076, Thermo Fisher Scientific) and read using Hidex Sense Beta Plus
plate reader (Turku, Finland). Treatments were performed in triplicates and expressed as
means. Drugs that showed modulation of MRP2 protein levels above 50% were selected
as hit compounds.
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3.0 Results
3.1 Screening of FDA approved drug library for modulators of MRP2
The FDA approved drug library containing 372 drugs was successfully screened using InCell ELISA assay using MRP2-overexpressing MDCKII cells. Treatments were performed
in triplicates, and experiments were done using the 96 – well format. The relative MRP2modulation by the FDA approved drugs is presented in Figure 4.2. Data obtained was
statistically analyzed and expressed as means. Drugs showing more than 50% modulation
on MRP2 protein expression were selected as “Hit compounds”. The results revealed 49
hit compounds that changed the MRP2 protein expression by more than 50%, representing
13.17% of total compounds screened. Among the identified hits for MRP2, 39 drugs
increased expression levels whereas 10 drugs lowered expression levels of MRP2 after
drug treatment as shown in Figure 4.3. Details on the hit test compounds identified from
screening are listed in Table 4.1 – 4.4.
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Figure 4.2: In-Cell ELISA assay screening for modulators of MRP2 protein
expression from a unique FDA approved drug library.
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Figure 4.3: Screening of 372 FDA approved drug library using In-Cell ELISA assay
Forty-nine (13.17%) hit compounds altered the MRP2 expression levels by more than 50%.
Thirty-nine (10.48%) drugs increased expression levels whereas 10 (2.69%) drugs lowered
expression levels of MRP2 after drug treatment.
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Table 4.1 List of hit compounds identified from FDA screening on MRP2 protein
expression
Drug

Target

% Modulation on
MRP1 protein levels a

Pralatrexate (Folotyn)

DHFR

-57.39 ± 3.85

Cetirizine Dihydrochloride

Histamine Receptor

106.29 ± 22.62

Mercaptopurine

DNA/RNA Synthesis

112.77 ± 15.36

Streptozotocin (Zanosar)

Nicotinamide

107.57 ± 13.87

adenine dinucleotide
Dexamethasone

IL Receptor

257.86 ± 10.58

Megestrol Acetate

Androgen Receptor

124.35 ± 26.22

Trilostane

Dehydrogenase

66.04 ± 4.96

Ranolazine dihydrochloride

Calcium Channel

93.67 ± 39.42

Repaglinide

Potassium Channel

94.45 ± 12.23

Sildenafil Citrate

PDE

70.30 ± 17.82

Gestodene

Estrogen/progestogen Receptor

54.07 ± 4.05

Isotretinoin

Hydroxylase

67.87 ± 5.05

Nafamostat Mesylate

Proteasome

84.25 ± 14.38

Ondansetron

5-HT Receptor

68.23 ± 7.83

Sodium Channel

75.54 ± 22.66

hydrochloride (Zofran)
Oxcarbazepine
a

Mean ± SD
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Table 4.2 List of hit compounds identified from FDA screening on MRP2 protein
expression
Drug

Target

% Modulation on
MRP1 protein levels a

Afatinib (BIBW2992)

EGFR, HER2

-62.24 ± 20.67

Gefitinib (Iressa)

EGFR

85.68 ± 14.81

Crizotinib (PF-02341066)

c-Met

56.41 ± 9.37

Sunitinib Malate

VEGFR, PDGFR, c-Kit, Flt

71.59 ± 11.40

Cladribine

DNA/RNA Synthesis

-74.96 ± 2.30

Evista (Raloxifene Hydrochloride)

Estrogen/progestogen Receptor

69.87 ± 7.06

2-Methoxyestradiol

HIF

148.42 ± 46.91

Asenapine

Adrenergic receptor,

-73.49 ± 5.67

5-HT receptor

a

Adrucil (Fluorouracil)

DNA/RNA Synthesis

-62.54 ± 1.78

Vincristine

Microtubule Associated

216.85 ± 46.37

Oxaliplatin (Eloxatin)

DNA/RNA Synthesis

100.88 ± 10.98

Mean ± SD
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Table 4.3 List of hit compounds identified from FDA screening on MRP2 protein
expression
Drug

Target

% Modulation on MRP1
protein levels a

Glyburide (Diabeta)

Potassium channel

-77.59 ± 3.61

Adefovir Dipivoxil (Preveon,
Hepsera)

reverse transcriptase

-87.87 ± 5.68

Sulfadiazine

Anti-infection

69.784 ± 19.01

Suprofen (Profenal)

COX-1/COX-2

108.14 ± 22.69

Cefditoren pivoxil

5-alpha Reductase

68.25 ± 9.12

Rifabutin (Mycobutin)

Antineoplastic and Immunosuppressive 96.66 ± 30.90
Antibiotics- Anti-infection

Esomeprazole Magnesium

proton pump

68.11 ± 20.06

Ethionamide

Anti-infection

52.59 ± 27.15

Vidarabine (Vira-A)

5-alpha Reductase

88.61 ± 18.51

Deferasirox (Exjade)

Ferroptosis P450 (e.g. CYP17)

78.46 ± 19.75

Methylprednisolone

Immunology and Inflammation related, 93.67 ± 25.54
Glucocorticoid Receptor, Interleukins,
ACE, Apoptosis related, Autophagy

Metolazone (Zaroxolyn)

Treatment congestive heart failure and 155.75 ± 34.37
high blood pressure

Darunavir

HIV Protease

56.94 ± 18.04

Glucocorticoid receptor

76.69 ± 23.89

(Nexium)

Ethanolate (Prezista)
Prednisone (Adasone)
a

Mean ± SD

124
Table 4.4 List of hit compounds identified from FDA screening on MRP2 protein
expression
Drug

Target

% Modulation on MRP1
protein levels a

a

Rasagiline Mesylate

MAO

-58.99 ±4.72

Dronedarone HCl

Anti-infection

-56.17 ± 5.53

Conivaptan HCl (Vaprisol)

vasopressin receptor

-57.59 ± 0.83

Eltrombopag (SB497115-GR)

c-mpl (TpoR) receptor

79.40 ± 18.03

Paeoniflorin

COX, HIF

53.80 ± 20.35

Benserazide

Dopamine Receptor

54.48 ± 22.74

Lovastatin

HMG-CoA Reductase

77.64 ± 17.81

Lafutidine

Histamine Receptor

55.36 ± 19.22

Erythromycin

Anti-infection,
Antibiotics

104 ± 18.32

Mean ± SD
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4.0 Discussion
Test compounds that modulated the protein expression levels of MRP2 in MDCKII/MRP2
cells above 50% (Hit compounds) in this study cuts across a broad spectrum of drug classes
and exhibit great diversity in their structure, molecular targets, and mode of action. This
included anticancer drugs, antibiotics, antivirals, anti-inflammatory drugs among others.
This finding reaffirms the promiscuous nature of the MRP2 transporter, and how important
it is to investigate the interaction between both old and newly developed drugs with MRP2.
Although several studies have aimed at investigating the impact of various therapeutic
agents on MRP2 efflux activity, it is needful that researchers also pay critical attention to
how these drugs may affect the protein expression levels of this transporter. From our
screening, about 10.48% of the hit compounds increased the expression of MRP2 protein
levels, this included drugs like vincristine (an anticancer drug), oxaliplatin (antineoplastic
medication), and irinotecan (an anticancer drug). MRP2 has been reported to be one of the
major ABC transporters that affect the bioavailability and therapeutic potency of anticancer
drugs in both polarized and unpolarized cells [10]. The anticancer drugs; Vincristine,
Oxaliplatin, and Irinotecan have earlier been reported in other studies as substrates of
MRP2 [7, 11, 12]. This indicates they are actively transported by MRP2/ABCC2
transporter thus the increase in MRP2 protein expression as observed in this study provides
the possible explanation that more MRP2 is expressed in these cells to catalyze and ensure
successful transport or efflux of these drugs across the plasma membrane.
Glucocorticoids like dexamethasone and prednisone also upregulated MRP2 protein
expression in our present screening. The ability of dexamethasone to increase the
expression levels of MRP2 protein as observed from the screening also reaffirms the
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observation reported by Narang and his colleagues [13] who reported that dexamethasone
increased expression and activity of multidrug resistance transporters at the rat blood-brain
barrier. Prednisone, on the other hand, has also been reported to induce the activity of the
MRP2 promoter [14], thus providing a possible reason for the increase in MRP2 protein
levels observed in this study. Methylprednisolone, another glucocorticoid with antiinflammatory and immunomodulating properties also upregulated MRP2 protein levels in
this screening. However to the best of our knowledge, the interaction between MRP2 and
methylprednisolone is yet to be reported, and it would be enlightening for further studies
to be carried out to investigate how these drugs may affect MRP2 activity. Erythromycin
(an antibiotic) and Lovastatin (a hypolipidemic agent and an HMG-CoA reductase
inhibitor) which has been reported by other studies to be substrates of MRP2 [15, 16] also
elevated the protein levels of MRP2 in this present study. Hence, this finding provides
useful information on the modulatory effect of these drugs that can be further explored.
Furthermore, findings from this study also suggest that anticancer drugs like Pralatrexate,
Afatinib, and Cladribine (an immunosuppressant) may decrease MRP2 protein expression
levels in MDCKII MRP2-overexpressing cells. Pralatrexate has been reported in earlier
studies to act as both a substrate and an inhibitor of MRP2 [17], interestingly, results from
our present study demonstrate that pralatrexate may downregulate the expression levels of
MRP2. Further investigation can be conducted to provide more insight into the effect of
pralatrexate on gene expression and other effectors that regulate MRP2 protein expression.
Moreover, the effect of pralatrexate on MRP2 protein expression levels in other MRP2overexpressing cell lines can be explored to confirm this initial finding. Afatinib is a known
moderate inhibitor of P-gp [18, 19], and a substrate /inhibitor of BCRP [19]. Results for
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this current study shows that Afatinib may reduce MRP2 protein levels. A thorough search
of current literature revealed that little is known about the impact of Afatinib on MRP2
activity and protein expression. Thus it would be enlightening to conduct further
investigation to confirm and ascertain how Afatinib affects the efflux activity of this
transporter in other MRP2 overexpressing cells. Cladribine is an FDA approved drug used
in the treatment of multiple sclerosis and hairy cell leukemia. It is a known substrate of
BCRP [20, 21] but proved otherwise on MRP2 when its impact on MRP2 membrane
vesicles was explored [22]. Nonetheless, cladribine downregulated the protein expression
levels of MRP2 in MDCKII MRP2 overexpressing cells in our present study. Thus it would
be illuminating to investigate the impact of cladribine on other MRP2-overexpressing cells
since the specific interactions between Cladribine and MRP2 remain uncertain. Further
probing using cell lines overexpressing this transporter would be a step in the right
direction. Adrucil (Fluorouracil), a DNA and RNA synthesis inhibitor that irreversibly
inhibits thymidylate synthase, and Asenapine, an antipsychotic medication belonging to
the dibenzooexpinopyrrole class [23] downregulated the expression levels of MRP2 in our
present study. To the best of our knowledge, the impact of Adrucil and Asenapine on MRP2
activity and expression has not been reported in literature.
Although HIV Protease Inhibitors (HPIs) have been reported to be substrates of MRP1 and
MRP2, the majority of tested HPIs are transported by MRP2. As such the overexpression
of MRP2 has great pharmacological implications on administered HPIs [24, 25]. Darunavir
Ethanolate is the ethanolate form of darunavir and an antiretroviral drug that inhibits the
human immunodeficiency virus type-1 (HIV-1) protease. In this present study, Darunavir
Ethanolate increased MRP2 protein expression in MDCKII overexpressing MRP2 cells.
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Although to the best of our knowledge, Darunavir Ethanolate has not been reported as a
substrate of MRP2, its ability to increase MRP2 protein levels suggests that this
antiretroviral drug may also be a victim of MRP2 efflux activity. Interestingly, Darunavir
the parent compound of Darunavir Ethanolate has been reported in other studies to induce
P-gp mRNA activity and expression in vitro as well as induce MRP1 protein expression in
CD4 (+) T cells from healthy human volunteers [26, 27]. On the Contrary, Adefovir
dipivoxil, a diester prodrug of adefovir and an antiviral medication used in the treatment
of chronic Hepatitis B infection in adults, also lessened the protein levels of MRP2 in this
screening. This is not surprising since adefovir is reported to be a known inhibitor of MRP2
[28]. However, no information has been reported on the interaction between this diester
derivative of adefovir and MRP2. It would be enlightening to investigate the modulatory
effect of Darunavir Ethanolate and Adefovir dipivoxil on MRP2 activity and expression in
other MRP2 overexpressing cells.
Our screening also identified other novel drugs whose effect on MRP2 activity or
expression levels are yet to be reported or explored to the best of our knowledge. This
included glyburide (medication for diabetes), Rasagiline mesylate ( medication for
Parkinson's disease), dronedarone HCl (antiarrhythmic drug), and conivaptan HCl
(vasopressin antagonist, endocrine-metabolic agent). These novel drugs downregulated the
protein expression levels of MRP2 in MDCKII MRP2-overexpressing cells in this study.
Other non-reported drugs that upregulated the expression levels of MRP2 in our present
study included Streptozotocin, Megestrol acetate, Gestodene, Trilostane, Ranolazine
dihydrochloride among others. This initial data on these novel drugs would provide foreknowledge that can further be explored. Like most proteins, MRP2 can be regulated at the
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transcriptional and post-transcriptional level. Studies have revealed that alterations in the
intracellular concentrations of bile acids and of a number of lipophilic compounds that are
ligands for nuclear hormone receptors can regulate MRP2/ABCC2 transcription levels [6].
Nuclear hormone receptors for hydrophobic molecules such as steroid hormones
(estrogens, glucocorticoids, progesterone, mineralocorticoids, androgens, vitamin D3,
ecdysone, oxysterols and bile acids), retinoic acids (all-trans and 9-cis isoforms), thyroid
hormones, fatty acids, leukotrienes and prostaglandins [29, 30]. Research has shown that
the hormone response element in rat MRP2/Abcc2 promoter (ER-8) is bound by
heterodimers of the retinoid receptor [31] with the ligand -activated transcription factors,
pregnane X receptor (PXR), farnesoid X receptor (FXR) or constitutive androstane
receptor (CAR). Thus various xenobiotics that regulate bile acid concentration can activate
these receptors which in turn upregulates the promoter region of the ABCC2 transporter
[32-36]. This finding provides a possible explanation to the increase in MRP2 protein
expression observed in this study after MDCKII/MRP2 cells were treated with Megestrol
acetate

(androgen

Methylprednisolone

receptor),
and

Gestodene

Prednisone

(estrogen/progestogen

(Glucocorticoid

receptor),

receptor),
and

Evista

(estrogen/progestogen receptor).
In summary, the modulatory effect of 372 drugs from a recently approved FDA drug library
on MRP2 protein expression in MDCKII/MRP2 cells was successfully screened using InCell ELISA assay. From this study, 49 hits compounds were identified to have altered the
MRP2 expression levels by more than 50%, representing 13.17% of total compounds
screened. Among the identified hits for MRP2, 39 drugs increased expression levels
whereas 10 drugs lowered expression levels of MRP2 after drug treatment. Although these
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identified hit compounds may be substrates, inhibitors, inducers, activators of MRP2, or
even false hits due to the non-specific interactions of MRP2 due to unknown reasons,
findings from this study bring to light the fact that MRP2 protein expression may be
affected by several drugs to a greater extent than imagined.
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Chapter 5
Relevant Contributions
1.0 Scope
This chapter focuses on relevant contributions and side projects undertaken towards the
general scholarly goals of our research group. After identifying novel modulators of MRP1
protein expression and activity in our initial screening of 30 drugs which comprised of
anticancer and FDA approved drugs as described earlier, we set out to screen a larger
number of drugs from different libraries to identify more modulators of MRP1 protein
expression. The first two projects in this session describe projects that were undertaken in
this direction. The first project aimed at the identification of chemotherapeutic drugs as
modulators of MRP1 protein expression in MRP1-overexpressing cells. In this project, we
screened 383 anticancer drugs from a unique anticancer library for their modulatory effect
on MRP1 protein expression in HEK293 MRP1-overexpressing cells using a high
throughput In-Cell ELISA assay. Our results from this study showed that some anticancer
drugs may modulate MRP1 protein expression and also demonstrated that the In-Cell
ELISA assay can be used as an effective high throughput tool for screening purposes.
Drugs that were identified can be used in developing therapeutics for treating tumors with
the MDR phenotype conferred by MRP1 overexpression.
The goal of the second project was to screen a recently approved FDA drug library to
identify modulators of MRP1 protein expression in HEK293 MRP1-overexpressing cells.
A total of 440 FDA drugs were successfully screened using In-Cell ELISA assay. These
drugs included antibiotics, antivirals, antidepressants among others. Our findings from the
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project suggest and affirm the fact that MRP1 interacts with a broad range of drug classes.
This signifies the importance of profiling the interaction of drugs with this transporter, and
the data obtained would provide essential information to improve drug efficacy and reduce
drug toxicity of various cancer chemotherapeutics and in diseases in which MRP1 is
implicated. In the third project, the effect of novel cucurbitacin-inspired estrone analogs
inhibitors of P-gp and MRP1 on P-gp and MRP1 protein expression was investigated.
These inhibitors were identified in an initial screening that was conducted by our research
group in another project. These inhibitors were further characterized using established cellbased methods, thus we ascertained the impact of these novel inhibitors on MRP1 and Pgp protein expression in human embryonic kidney overexpressing P-gp cells (HEK293/Pgp) and small cell lung cancer cell line (H69AR) using western blot assay.
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Identification of chemotherapeutic drugs as modulators of Multidrug Resistance
Protein 1 (MRP1) expression in HEK293 MRP1- overexpressing cells
Introduction
We recently identified some novel modulators from our initial screening of thirty
compounds on MRP1 protein expression in HEK293 MRP1-overexpressing cells. These
drugs consisted of both clinically tested anticancer drugs and some recently approved FDA
drugs. From our initial screening, we identified that anticancer drugs; SB743921 HCl,
Amuvatinib, TG101348 (SAR302503), and a FDA-approved drug; Felbamate, may
modulate MRP1 protein expression in HEK293 MRP1-overexpressing cells. Further
characterization of these compounds using cell-based established assays revealed that
SB743921 HCl, Amuvatinib, TG101348 downregulate MRP1 efflux activity, with
Amuvatinib and TG101348 being potent reversers of MRP1 mediated MDR in these cells.
Based on these interesting findings we decided to screen different drug libraries containing
a larger number of drugs to investigate their effect on MRP1 protein expression. Using InCell ELISA assay, we explored the effect of 383 clinically-tested anticancer drugs from a
unique anticancer drug library for their effect on MRP1 protein expression in HEK293
MRP1-overexpressing cells. These drugs from the anticancer library consisted of small
molecules under clinical trials for 12 different types of cancers.
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Materials and methods
Chemicals
Anticancer compound library consisting of 383 anticancer small molecules under clinical
trials for 12 different types of cancers was procured from Selleck Chemicals (Houston,
TX). Super signal West Dura® extended duration chemiluminescence substrate
(21EAPI34076) was purchased from Thermo Fisher Scientific (Waltham, MA).
Cell lines and cell culture
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD) respectively. Dulbecco’s modiﬁed Eagle medium
(DMEM) (GE Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine
serum (FBS) was used to grow the HEK293 cell lines. Cell lines were cultured in a
humidiﬁed incubator maintained at 5% CO2 and 37°C. This incubation condition was
retained in all subsequent cell culture procedures.

Screening of anticancer library using In-Cell ELISA assay
Cells were seeded at 5x104 cells per well in 96- well plates with DMEM containing 10%
FBS and incubated for 24 hours at 37°C. Cells were treated with drugs (10uM), 0.1%
DMSO for controls and incubated for 48 hours at 37°C. At the end of the incubation period,
treatment was removed and cells were rinsed twice with 150 μL of PBS. Cells were fixed
with 3.7% paraformaldehyde and permeabilized with Triton-X 100. The cells were blocked
with fish gel (MB-066-0100, Rockland) and incubated overnight at 4 °C with monoclonal
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anti-MRP1 antibody (IU5C1, MA516079, Thermo Fisher Scientific) or anti-α tubulin
antibody (T5168, Sigma-Aldrich) at 1:500 and 1:1000 dilutions, respectively. Secondary
antibody incubation was performed using horseradish peroxidase-conjugated goat antimouse IgG (H + L) (Thermo Fisher Scientific) for an hour at room temperature. Target
proteins were detected using Super Signal West Dura® Extended Duration
chemiluminescence substrate (21EAPI34076, Thermo Fisher Scientific) and read using
Hidex Sense Beta Plus plate reader (Turku, Finland). Experiments were conducted in two
independent studies and treatments were performed in duplicates. Dunnett test was applied
for multiple comparisons, statistical testing was performed at a 5% level of significance.

141
Results and Discussion
Screening of anticancer compound library for modulators of MRP1 protein
expression
The anticancer library containing 383 drugs was successfully screened using In-Cell
ELISA assay. Two independent experiments were conducted in the 96-well format. The
relative MRP1-modulation activity of the anticancer drugs from the two independent
experiments is represented as a 2D scatter plot (Figure 5.1). As indicated in Figure.
5.1(bottom), the assay had good reproducibility with a correlation range of 0.71 between
the two given experiments. Differences between the two groups were determined by the
Student’s t-test using excel, and correlation analysis was evaluated by Pearson’s correlation
using R studio version 3.5.2. Dunnett test was applied for multiple comparisons, statistical
testing was performed at a 5% level of significance. Figure 5.2 shows the effect of the
various anticancer drugs screened on MRP1 protein expression in HEK293/MRP1 cells.
Screening of the 383 anticancer drugs revealed 89 hit compounds that changed the MRP1
expression by 50% or more, representing 23.2% of total compounds screened. Among the
identified hits, 57 drugs increased expression whereas 32 drugs lowered expression of
MRP1 after drug treatment as shown in Figure 5.3. The identified hit compounds included
known MRP1 substrates like doxorubicin, vincristine, etoposide, and dexamethasone [1,
2]. Some novel MRP1 modulators were also identified in this initial screening whose
interaction or relationship with MRP1 have not been reported. These novel modulators may
be substrates, inhibitors, inducers, or activators of MRP1. Some may also be false hits due
to the non-specific interaction with MRP1 for unknown reasons. However, these novel
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modulators identified would be further validated and characterized by our research group
in future studies.

Correlation coefficient
Experiment

1

2

1

1

0.71

2

0.71

1

Figure 5.1 Screening of Anticancer drug library using In-Cell ELISA assay
The screening was conducted in two independent studies at a compound concentration of
10uM. The table below the plot shows correlation coefficients between the experiments.
Correlation coefficient calculated and 2D graph generated using R studio version 3.5.2.
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Figure 5.2 Effect of Anticancer drugs on MRP1 protein expression levels in
HEK293/MRP1 cells from screening using In-Cell ELISA assay

Figure 5.3 Screening of 383 anticancer drug library using In-Cell ELISA assay
Eighty-nine (23.24%) hit compounds modulated the MRP1 expression levels, with 57
(14.88%) drugs increased expression levels whereas 32 (8.36%) drugs lowered expression
levels of MRP1 after drug treatment.
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Identification of FDA approved drugs as modulators of Multidrug Resistance Protein
1 (MRP1/ABCC1) expression in MRP1-overexpressing cells
Introduction
MRP1 is reported to affect the efficacy and bioavailability of drugs belonging to various
drug classes aside from anticancer drugs [3]. We decided to explore the effect of other
therapeutic agents from other drug families on MRP1 protein expression in HEK293
MRP1-overexpressing cells. We achieved this by screening 440 FDA drugs from a recently
approved FDA drug library to ascertain their effect on MRP1 protein expression. This FDA
approved drug library consisted of structurally diverse therapeutic agents that belonged to
different drug families. This includes antivirals, antibiotics, antidepressants, antiinflammatory drugs as well as drugs used in the treatment of cardiology, immunology,
neuropsychiatry-related conditions.
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Materials and methods
Chemicals
FDA (Food and Drug Administration) approved drug library was procured from Selleck
chemicals (Houston, TX). Super signal West Dura® extended duration chemiluminescence
substrate (21EAPI34076) was purchased from Thermo Fisher Scientific (Waltham, MA).

Cell lines and cell culture
HEK293/pcDNA3.1 and HEK293/MRP1 cells were a kind gift from Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD) respectively. Dulbecco’s modiﬁed Eagle medium
(DMEM) (GE Healthcare, Marlborough, MA, USA) supplemented with 10% fetal bovine
serum (FBS) was used to grow the HEK293 cell lines. Cell lines were cultured in a
humidiﬁed incubator maintained at 5% CO2 and 37 °C. This incubation condition was
retained in all subsequent cell culture procedures.

Screening of FDA approved drug library using In-Cell ELISA assay
In-Cell ELISA assay was performed by seeding HEK293/pcDNA 3.1 and HEK293/MPR1
cells at a cell density of 5x104 cells per well in 96- well plates with Dulbecco’s Modified
Eagle Medium supplemented with 10% fetal bovine serum. Cells were treated with
drugs(10uM), DMSO (control and Parental) after 24 hours (95% confluency), and
incubated for 48 hours at 37 °C. At the end of the incubation period, treatment was removed
and cells were rinsed twice with 150 μL of PBS. Cells were fixed with 3.7%
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paraformaldehyde and permeabilized with Triton-X 100. The cells were blocked using fish
gel (MB-066-0100, Rockland) and incubated overnight at 4 °C with monoclonal antiMRP1 antibody (IU5C1, MA516079, Thermo Fisher Scientific) or anti-α tubulin antibody
(T5168, Sigma-Aldrich) at a 1:1000 dilution, respectively. Secondary antibody incubation
was performed using horseradish peroxidase-conjugated goat anti-mouse IgG (H + L)
(Thermo Fisher Scientific) at a dilution of 1:1000 for an hour at room temperature. Target
proteins were detected using Super Signal West Dura® extended duration
chemiluminescence substrate (21EAPI34076, Thermo Fisher Scientific), and read using
Hidex Sense Beta Plus plate reader (Turku, Finland). Treatment was performed in
triplicates. Data obtained were statistically analyzed to calculate the mean and percentage
modulation. Drugs that showed modulation above 50% were considered as Hit compounds.

Results and discussion
Screening of FDA approved drug library for modulators of MRP1
The FDA approved drug library containing 440 drugs was successfully screened using InCell ELISA assay. The FDA approved drug library was screened using HEK293 MRP1overexpressing cells. Treatments were performed in triplicates, and experiments were done
using the 96-well format. The relative MRP1-modulation activity of the FDA approved
drugs are shown according to plates screened as presented in Figure 5.4. The mean and
percentage modulation of the drugs screened were calculated using Microsoft excel. Drugs
showing more than 50% modulation on MRP1 were selected as hit compounds. Screening
of the 440 FDA-approved drugs on HEK293/MRP1 cells revealed 70 hit compounds that
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modulated the MRP1 expression levels by 50% or more representing 15.90% of total
compounds screened. Among the identified hits, 56 drugs increased expression levels
whereas 14 drugs lowered expression levels of MRP1 after drug treatment as shown in
Figure 5.5. Findings from our initial screening showed that aside anticancer drugs, drugs
from other drug classes can also modulate MRP1 protein expression. The identified hit
compounds included antivirals, anticonvulsants, anti-inflammatory, antiestrogen agents
among others. The modulators identified in this study would be further investigated and
characterized by our research group in future projects.

Figure 5.4: Screening of 440 FDA approved drug library using In-Cell ELISA assay
Seventy hits compounds (15.91%) changed the MRP1 protein expression by more than
50%. Fifty-six drugs (12.73%) increased expression levels whereas 14 drugs (3.18%)
lowered expression levels of MRP1 after drug treatment.
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Figure 5.5: Screening of 440 FDA approved drug library using In-Cell ELISA assay
Seventy (70) hit compounds (15.91%) that changed the MRP1 expression levels by more
than 50%. 56 drugs (12.73%) increased expression levels whereas 14 drugs (3.18%)
lowered expression levels of MRP1 after drug treatment.
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Effect of novel cucurbitacin-inspired estrone analogs on the protein expression levels
of P-glycoprotein (P-gp) and Multidrug resistance protein 1 (MRP1)
Introduction
Natural compounds including phytochemicals have been established as compounds that
can modulate the activity of ABC transporters including MRP1 and P-gp. Polyphenols like
curcumin, and bioflavonoids like apigenin, quercetin have been reported to have a
significant effect on the transport activity of MRP1 [4, 5]. Recently, in an ongoing project,
we screened some cucurbitacin-inspired estrone analogs to identify inhibitors of Pglycoprotein (P-gp) and Multidrug resistance protein 1 (MRP1) in human embryonic
kidney overexpressing P-gp cells (HEK293/P-gp) and small cell lung cancer cell line
(H69AR) respectively. We identified 8 of these analogs to show inhibitory effects on P-gp
activity in HEK293/P-gp whereas 4 of these analogs also strongly inhibited MRP1 in
H69AR. These inhibitors have further been characterized using established cell-based
assays. We further investigated the influence of these novel inhibitors on P-gp and MRP1
protein expression using western blot assay.
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Materials and methods
Cell lines and cell culture
H69 and H69AR cells were purchased from ATCC (Manassas, VA). HEK293/pcDNA3.1
and HEK293/P-gp were kindly gifted by Dr. Suresh V. Ambudkar (NIH, Bethesda, MD).
Dulbecco’s modiﬁed Eagle medium (DMEM) (GE Healthcare, Marlborough, MA, USA)
supplemented with 10% fetal bovine serum (FBS) was used to grow the HEK293 cell lines.
H69 cell lines were cultured in RPMI 1640 (ATCC) media supplemented with 10% FBS.
H69AR cells were monthly exposed to 0.8 mM doxorubicin and cultured without drug
treatment for 1 week before use in experiments. Cells were cultured at 37 °C in a
humidified incubator set at 5% CO2.

Western blot assay
HEK293 and H69 cell lines were seeded at cell densities of 7x105 and 1x106 cells in 6well plates respectively in a culture medium. Cells were treated with drugs (10 µM), and
0.1% DMSO for controls after 24 hours, and incubated for 48 hours at 37 °C after drug
treatment. At the end of the incubation period, treatments were removed and cells were
rinsed with 1000 μL of PBS. The cells were lysed with lysis buffer containing RIPA buffer
(Thermo Fisher Scientific, Waltham, MA) supplemented with 1× halt protease inhibitor.
Protein concentration was determined with the Pierce BCA protein assay kit (Thermo
Fisher Scientific, Waltham, MA). Proteins (20 μg) were loaded in each well on 8.0% mini
sodium dodecyl sulfate (SDS) gels, and SDS page electrophoresis was conducted. Proteins
were transferred to Immobilon PVDF membranes (EMD Millipore, Burlington, MA). The
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membrane was blocked and incubated overnight at 4 °C with rabbit monoclonal anti-MRP1
antibody [EPR21062](1:250; Abcam, ab233383) and anti-alpha-tubulin antibody (1:5000;
Sigma-Aldrich) respectively. Followed by incubation with secondary antibody for an hour
at room temperature using horseradish peroxidase-conjugated goat anti-mouse IgG(H+L)
(1:1000; Thermo Fisher Scientific) for alpha-tubulin, and horseradish peroxidaseconjugated goat-anti-rabbit IgG(H+L) (1:1000; Thermo Fisher, Scientific) for detection of
MRP1. Target proteins were developed using a Western blotting luminol reagent (Santa
Cruz Biotechnology, sc-2048) and an LI-COR Odyssey Fc imaging system. Protein band
densities were quantified and analyzed using Image Studio Lite version 5.2 (LI-COR
Biotechnology, Lincoln, NE), and uneven sample loading and transfer was corrected using
the intensity of the corresponding protein band relative to the alpha-tubulin (loading
control) band. The experiment was conducted in three independent studies. The data
obtained was statistically analyzed and the Dunnett test was applied for multiple
comparisons, statistical testing was performed at a 5% level of significance.

152
Results and Discussion
Effect of test compounds on P-gp and MRP1 protein expression levels
We determined the effect of these novel cucurbitacin-inspired estrone analogs which were
identified as inhibitors in our initial screening on protein expression of P-gp and MRP1.
Our results as shown in Figure 5.6 and Figure 5.7 indicate that these inhibited do not have
a significant impact on P-gp and MRP1 protein expression in HEK293/P-gp and H69AR
cells.

Figure 5.6: Effect of novel cucurbitacin-inspired estrone analogs on protein expression of
P-gp in HEK293/P-gp cells
[A, B] Shown are representative western blots of whole-cell lysates (20 ug of protein/lane)
prepared from drug treatment (10 uM) on HEK293/P-gp cells. P-gp proteins and alphatubulin was detected using monoclonal P-gp antibody [C219] (GTX23364,GeneTex) and
anti- alpha-tubulin antibody (Sigma-Aldrich) at 1:250 and 1:5000 dilutions, respectively.
Secondary antibody incubation used performed using GAM (mAb – goat- anti-mouse)
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(1:10000). [C, D] Dunnett test was applied for multiple comparisons, statistical testing was
performed at a 5% level of significance, and the graph was developed using Graph Pad
Prism version 6.

Figure 5.7 Effect of novel cucurbitacin-inspired estrone analogs on protein expression
MRP1in H69AR cells.
[A] Shown are representative western blots of whole-cell lysates (20 ug of protein/lane)
prepared from H69AR cells treated 10 µM of test compounds. MRP1 proteins were
detected with monoclonal anti-MRP1 antibody [EPR21062](ab233383, Abcam) and antiGAPDH antibody (Sigma-Aldrich) at a dilution of 1:250 and 1:1000 respectively.
Secondary antibodies; mAb - anti-rabbit and mAb-anti-goat were used at a dilution of
1:1000. [B] Dunnett test was applied for multiple comparisons, statistical testing was
performed at a 5% level of significance, and graph was developed using Graph Pad Prism
version 6.0.
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Chapter 6
Final discussions and General conclusions
The overexpression of ABC transporters in tumor cells has been reported to be responsible
for the multidrug resistance (MDR) phenotype observed in several carcinomas. The role of
ABC transporters like P-gp and BCRP in the MDR of tumor cells has been well
investigated in clinical cancer research. However, recent studies have revealed that ABC
transporters; MRP1 and MRP2 are also major players in the development of MDR in
several carcinomas [1, 2]. MRP1 was discovered by Cole and her colleagues when they
observed the overexpression of a transporter gene in a multidrug-resistant human lung
cancer cell line (H69AR) which did not overexpress P-gp [3]. The plasticity of the binding
site of this transporter enables it to interact with a variety of substrates, which mostly
include amphipathic organic acids with large hydrophobic groups [4]. This ubiquitous
transporter is reported to mediate the transport of heavy metals, organic anions,
glucuronide-conjugates of steroids, prostaglandins, drugs, and their metabolites across
biological membranes [5, 6]. Due to its transport activity, MRP1 governs the absorption
and disposition of drugs and their metabolites across cells. MRP2 which is popularly
known as canicular multi-specific organic anion transporter 1 (cMOAT) [7] also facilitates
the transport of xenobiotics and endogenous compounds to the bile, urine, or feces [8]. Due
to the pivotal roles of MRP1 and MRP2 in the transport and distribution of drugs and their
metabolites, their overexpression has been associated with reduced intracellular
concentration and bioavailability of various classes of drugs (vinca alkaloids,
anthracyclines, antibiotics, protease inhibitors) [8-11] in tumor cells. As such, these
transporters have been implicated in MDR of several solid human tumors like kidney,
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colon, breast, lung, and ovarian carcinomas [12]. Strategies to overcome the MRP1 and
MRP2 mediated MDR in tumors involve the identification of modulators of these
transporters which can regulate their activities in tumor cells without interrupting their role
in maintaining physiological equilibrium in normal cells. Although some modulators of
MRP1 and MRP2 have been identified in recent times, most of the current modulators that
have been identified are limited by non-specific toxicity, low MDR reversal effects, and
low therapeutic efficacy in in-vivo experiments. Thus there is the need for the identification
of more potent and safer modulators of MRP1 and MRP2.
In this present study, we aimed at identifying modulators of MRP1 and MRP2 by screening
therapeutic agents from various drug libraries using In-Cell ELISA assay. Our initial
screening of 30 compounds, identified a total of 7 test compounds that modulated MRP1
protein expression in HEK293 MRP1-overexpressing cells by 50% or more. Four of the
test compounds; Vismodegib (GDC-0449), TG101348 (SAR302503), Amuvatinib, and
SB743921 HCl decreased the protein expression levels of MRP1, and three test
compounds; Epirubicin HCl, Felbamate, and Irinotecan increased the protein expression of
MRP1. Three of these modulators (Epirubicin HCl, Irinotecan, Vismodegib (GDC-0449)
had already been reported in other studies [13-15], thus were not considered for further
characterization in this study. Four of the identified modulators exerted novel modulatory
activity on MRP1 protein expression. This included ATP competitive inhibitors;
SB743921 HCl, Amuvatinib, TG101348 (SAR302503), and Felbamate ( a recently
approved FDA drug). SB743921 HCl, Amuvatinib,

and TG101348 (SAR302503)

downregulated MRP1 protein expression in HEK293 MRP1-overexpressing cells whereas
Felbamate increased MRP1 protein expression. Our findings from this study also showed
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that SB743921 HCl and Amuvatinib decreased MRP1 protein expression in HEK293
MRP1-overexpressing cells in a concentration and time-dependent manner. SB743921
HCl, Amuvatinib, and TG101348 (SAR302503) inhibited the growth of these cells at
clinically achievable concentrations. Moreover, we report that Amuvatinib and TG101348
(SAR302503) reverse MRP1 mediated resistance against vincristine in HEK293 MRP1overexpressing cells.
We also demonstrated that for the first time that Tie2 kinase inhibitor can inhibit MRP1
mediated calcein efflux in HEK293 MRP1-overexpressing cells. Moreover, Tie2 kinase
inhibitor was able to reduce the fold resistance of HEK293 MRP1-overexpressing cells
towards vincristine. Everolimus, an mTOR inhibitor that was previously reported by our
lab group to be an inhibitor of MRP1 in H69AR cells, also inhibited MRP1 mediated
calcein efflux in HEK293 MRP1-overexpressing cells. Everolimus also reversed MRP1
mediated resistance in HEK293 MRP1-overexpressing cells. Findings from this study
show that these therapeutic agents may be useful for developing combinatorial therapy
targeting malignancies involving MRP1.
Furthermore, we also screened a recently approved FDA approved library for modulators
of MRP2 using In-Cell ELISA. This unique FDA drug library comprises drugs from
different drug classes including antivirals, antibiotics, antidepressants, antihypertensives
among others. Our screening of 372 FDA drugs identified 49 modulators of MRP2 in
MDCKII MRP2-overexpressing cells. Thirty-nine of these modulators increased MRP2
expression whereas 10 compounds lowered MRP2 expression levels after drug treatment.
The ability of MRP2 to be modulated by compounds from different drug families that
exhibit great structural diversity in this study indicates that MRP2 is a promiscuous
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transporter. As such this transporter can interact with several compounds irrespective of
their structure and drug classification. Modulators identified in this study would be further
characterized in future projects.
On the whole, we identified modulators of MRP1 and MRP2 protein expression and
activity. These modulators can be used in the development of combinatorial drug therapy
for MRP1 and MRP2 targeted therapeutics. Our findings indicate the importance of
investigating the possible drug-interactions between various therapeutic compounds with
these transporters. Research into drug-transporter interactions would provide a better
understanding of the physiology of these transporters and the pharmacology of these
therapeutic agents. Thereby creating a platform for optimizing drug treatment for
chemotherapy and other MRP1/MRP2 related malignancies.
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